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ABSTRACT 
The complexation of drugs with alpha, beta, gamma and 
hydroxyethyl beta cyclodextrins was investigated using the 
solubility method described by Higuchi and Connors . Beta 
cyclodextrin was shown to exhibit the most extensive 
complexation. The solubility isotherms of complexation were 
studied at different temperatures and at various pH 
conditions. The effect of ionization of drugs on 
complexation was thus evaluated for four drugs viz 
phenytoin, diazepam, ibuprofen and hydrochlothiazide. In the 
case of phenytoin and diazepam, both the non-ionized and the 
ionized species were shown to form a complex with 
cyclodextrins. The slope of complexation for ibuprofen and 
hydrochlorothiazide was found to be pH-independent. The 
thermodynamic parameters of complexation were determined 
using the temperature dependence method. In order to 
characterize more specifically the parameters of 
complexation, a novel computerized method was then 
developed. A non-linear regression software was used to 
evaluate the values of the complexation parameters as well 
as their standard deviation and 95% confidence limit. The 
complexation of drugs with hydroxyethyl beta cyclodextrin 
showed that the substitution of the natural cyclodextrin 
affected the solubility of the complexing agent without 
altering its solubilizing power. A rule of prediction was 
then proposed, allowing the calculation of potential drug 
concentration upon complexation with the cyclodextrin 
derivative. The ratio of solubility of the two kinds of 
cyclodextrins was shown to correlate very well with the 
ratio of the concentration of drug complexed. The rule 
might be applied to all drugs at various pH values. The 
potential use of beta cyclodextrin as an additive in 
tableting was also evaluated. The mechanism of dissolution 
rate enhancement was found to be related not only to the 
inclusion complex formation but also to mechanical changes 
during the mixing process. 
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PREFACE 
This dissertation follows the format of the MANUSCRIPT 
PLAN, as described in section 11-3 of the Graduate Manual of 
the University of Rhode Island. The work is presented in 
three sections. Section I contains the introduction to the 
project and the objectives of the study. Section II 
consists of five manuscripts, which represent the core of 
the study. At the time of the defense, three manuscripts 
will have been either accepted or at least submitted to 
international scientific journals. The two other 
manuscripts are written according to the format suitable for 
publication. Section three consists of the specific details 
related to the various aspects of the study. The appendices 
thus describe either certain experimental considerations or 
computer manipulations. Appendix A is a manuscript 
published in Drug Development and Industrial Pharmacy, that 
is related to a study performed at Miles Pharmaceuticals, 
West Haven, CT, where the author of this thesis was awarded 
a Graduate Student Summer fellowship. Appendix B reports a 
study performed at the University of Rhode Island, in 
association with Dr. J. L. Kanig, who is an adjunct 
Professor in the Department of Pharmaceutics. Appendices C 
to I allows the reader to repeat certain procedures or to 
obtain more details regarding the computer work. 
vii 
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INTRODUCTION 
Many of the new chemical entities recently synthesized 
or discovered in the pharmaceutical industry possess poor 
physico-chemical properties, which impact adversely on 
formulation. Thus low solubility, limited stability and 
erratic bioavailability sometimes make the development of 
acceptable dosage forms impossible. In addition, some 
drugs formely discarded for their formulation problems have 
recently attracted new interest. One major new tool of 
solubilization and stabilization of drugs in the 
pharmaceutical industry has been the use of cyclodextrins. 
cyclodextrins are cyclic oligosaccharides . The three 
major forms of cyclodextrins viz a, ~ and ~ consist of six, 
seven or eight units of glucose, respectively (1). The size 
of the cavity of these molecules gives the unique 
opportunity to adjust the affinity between the drug and the 
complexing agent, and therefore to optimize the 
complexation (2). There has been keen interest in the 
phenomenon of cyclodextrin complexation for the past decade 
or so, in the field of chemicals, agriculture and 
pharmaceuticals (3,4,5) as well as in the food industry. 
The affinity of certain molecules for cyclodextrins has been 
the basis of many applications of cyclodextrin conplexation. 
Cyclodextrins have been used as enzymatic model in 
biochemistry and as a separation material in analytical 
2 
chemistry (6). The terms clathrate, complex, inclusion 
compound and monomolecular encapsulate have all been used to 
refer to cyclodextrin complexation. 
Within the pharmaceutical industry, there are three 
advantages to cyclodextrin complexation: 
a) the improvement of solubility, dissolution rate and 
bioavailability (7,8,9); 
b) the stabilization of drugs (10,11); 
c) the amelioration of organo-leptic properties such as 
smell or taste. 
Numerous excellent reviews of the sub ject of 
complexation of drugs with cyclodextrins have been published 
in the past few years. Special references will be given to 
two books, edited by Sjeztli (1) and Duchene (3). The 
review articles by Uekama (4) and Hegde (12) give a complete 
overview of history, structure, toxicity, uses and 
limitations of cyclodextrins in the pharmaceutical industry. 
Numerous publications have appeared in the literature, 
especially from Japan, during the past ten years. The 
structure of the work done is usually presented as a 
sequence of four steps (13,14,15): 
a) results showing the complexation of the drug considered 
with cyclodextrin using the solubility method, spectroscopy, 
conductivity or diffusion; 
b) preparation of the complex by freeze-drying or solvent 
evaporation; 
3 
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c) results of the physical properties of the complex 
prepared using Proton Magnetic Resonance (PMR), X-Ray 
crystallography, Infra-Red spectroscopy or Differential 
Scanning Calorimetry (DSC), and elucidation of the 
stoichiometry of the complex; 
d) evidence of the advantages of complex formation by 
in-vitro dissolution studies or in-vivo animal 
bioavailability results. 
The two areas lacking in-depth work have been the 
design of dosage forms of the drug / cyclodextrin complex, and 
the study of the physico-chemical aspects of the 
complexation phenomenon. 
In this introduction the different aspects of 
cyclodextrin complexation, which have been suggested and 
discussed in the literature, will be briefly reviewed. 
Special attention will be then given to the physical 
chemistry and the thermodynamics of complexation . The two 
main thermodynamic parameters considered will be the 
enthalpy, which corresponds to the heat exchange upon 
complexation, and the entropy, which may be largely regarded 
as reflecting the degree of order of the system. In 
addition, the current regulatory status of cyclodextrins in 
the Food and Drug industry world-wide will be discussed. 
The mechanism of complexation of drugs with 
cyclodextrins is based on some basic characteristics of the 
cyclodextrin molecules. Each glucose unit included in the 
ring contains three hydroxyl groups : C(2) and C(3) are 
secondary hydroxyl whereas C(6) is a primary hydroxyl. 
These hydroxyl groups are also of critical importance in the 
preparation of cyclodextrin derivatives, which have been 
synthetized and have great potential applications in the 
pharmaceutical industry (16). The hydroxyl groups laying on 
the outer surface of the ring give to the cyclodextrin 
molecule its hydrophilicity . The inside of the cavity is 
hydrophobic due to the glucosic oxygen bridges. Upon 
complexation, the apolar guest molecule will approach the 
host molecule of cyclodextrin and will fit into the cavity. 
The mechanism of cyclodextrin complexation in water or 
aqueous buffered solutions is closely related to the nature 
of the solvent. Water can be considered as a mixture of 
free water molecules and structured material. The water 
molecules are subject to hydrogen bonding; when a large 
number of hydrogen bonds are established, a structure called 
clusters or ice-like hydrogen bonded material is formed 
(17). From a thermodynamic point of view, water is thus a 
very versatile solvent, with continual formation and rupture 
of hydrogen bonds. Water will influence the thermodynamics 
of complexation at two different levels: the water molecules 
trapped inside the cyclodextrin cavity are iceberg- like and 
enthalpy- rich, and a non-polar molecule will be also 
surrounded by structured water, likely to be perturbed upon 
complexation . 
The complex formation can be represented by the schemes 
shown in Figures 1 and 2. Figure 1 represents the non polar 
5 
aromatic ring of a potential guest molecule, that will 
replace the energetically rich water molecules from the 
inside of the cyclodextrin cavity. The result of this 
displacement will be a favorable non polar / non polar 
interaction. A more detailed representation is shown in 
Figure 2. 
The different steps occuring during the complexation 
formation process have been proposed as follows (18,19): 
a) the guest molecule or drug approaches the cyclodextrin 
molecule; 
b) the ice-like water trapped in the cyclodextrin cavity is 
displaced, with loss of structure and corresponding release 
of energy; 
c) the water molecules surrounding the apolar portion of the 
drug to be included are broken down and water molecules go 
into solution; 
d) substituents of the drug interact with either the rim or 
the inside of the cyclodextrin ring; 
e) hydrogen bonds may be formed between the drug and 
cyclodextrin; 
fl the water structure is reestablished around the drug and 
cyclodextrin. 
The question of the exact driving force in complex 
formation has been subject to controversy. The different 
theories proposed are as following: 
1. Hydrophobic interaction 
c 
The water molecules around the apolar drug are broken 
down. The increased degree of freedom of the liberated 
water molecules corresponds to a negative entropy and a 
positive enthalpy upon complexation. 
2. Van der Waals interaction 
This type of interaction can originate either from 
dipole / dipole (Keesom forces), dipole / induced dipole (Debye 
forces) or induced dipole / induced dipole (London forces) 
interaction. The Van der Waals forces are weak and are 
unlikely to establish stable complexes by themselves. These 
forces would correspond to a negative enthalpy and a 
negative entropy. 
3. Hydrogen bonding 
The inclusion complex formation involves three components: 
the drug or guest molecule, the cyclodextrin or host 
molecule and the solvent. Different possibilities of 
interaction exist between these three components. Not only 
drug and cyclodextrin can interact, but also the solvent 
interacts with both the drug and the cyclodextrin. Some 
substances have been shown to function as Hydrogen bond 
donors. However this mechanism of complexation is generally 
regarded of minor importance, since the average bond energy 
-1 is only 2 to 8 Kcal.mol . 
4. Release of high energy water 
Water can be considered as existing with two different 
structures: water molecules can be tightly bound to 
water-solvating charged sites to form hydrogen bonding; 
water molecules enclosed within the cyclodextrin cavity 
cannot have a full complement of hydrogen bonds and are 
enthalpy-rich. The expulsion of these enthalpy-rich water 
molecules into bulk water upon complexation seems to be a 
major factor in the mechanism . The thermodynamic parameters 
observed in this case are usually a negative enthalpy and a 
negative entropy. 
5. Release of conformational strain 
This mode of action should be especially of critical 
importance in the case of alpha cyclodextrin complexation, 
that has the lowest number of glucos e units. The torsion of 
the cyclodextrin molecules would be affected upon 
penetration of the guest molecule into the cavity, thus 
releasing energy. 
Even though no general rule has been entirely accepted, 
it appear s that a combination of the different factors 
described earlier is likely to play a role in the complex 
formation. The relative combination of each factor will 
depend upon the drug and the type of cyclodextrin. However, 
the definite point of agreement is that the thermodynamics 
of complexation deserve attention and clarification. It is 
generally accepted that both the extent and the sign of the 
3 
thermodynamic parameters viz enthalpy and entropy will give 
a clear indication of the process involved. Furthermore, a 
variation of pH. leading to a change in the ionization of 
the drug will undoubtedly affect the polarity of the drug, 
thus influencing the complexation phenomenon. 
One major concern in the pharmaceutical industry has been 
the regulatory status of cyclodextrins. The nature of the 
interaction forces involved in the drug / cyclodextrin complex 
formation should give to the final product the status of 
materials such as solid dispersions , which means that a 
simplified approval process with no recognized new chemical 
entity may apply. In order to be approved for commercial 
use in food and drug products, a compound has to be 
Generally Regarded As Safe (GRAS) and usually a Drug Master 
File (DMF) will then be established with the Food and Drug 
Administration (FDA). The acceptance of a DMF is based of 
the results of clinical, toxicological and metabolic 
studies. Usually not only acute toxicity results, but also 
results from chronic use of the substance are required by 
the FDA. In the case of cyclodextrins, it appears that 
acute and chronic toxicity have been carried out in rats and 
dogs, but there is limited long term toxicity data. A 
report by the Food and Agriculture Organization (FAO) 
classified cyclodextrins as enzymatically modified starches. 
This position seems to be confirmed by various European 
Health Agencies, which also recently considered ~ 
Q 
cyclodextrin as an enzymatically modified starch. Since 
1983, the use of ~ cyclodextrin is thus approved for 
stabilization of flavors. In 1986, France granted approval 
for the use of ~ cyclodextrin as a flavor carrier. A major 
breakthrough in the approval process has been the efforts of 
a Dutch starch company, Aebe, to gather data and to gain 
approval in Netherlands, Belgium and Luxemburg . German and 
Spanish authorities seem to follow the same position and are 
expected to approve cyclodextrins for food products (20). 
However, as far as the drug industry is concerned , the only 
products on the market world-wide are 
Prostaglandin/ cyclodextrin complexes in Japan. Thus, Ono 
Pharmaceuticals has launched a tablet formulation in 1976 
and an injectable dosage form in 1979 (21). 
The objectives of this study were: 
1. To contribute to the characterization of the 
physico-chemical parameters that control the complexation 
of drugs with cyclodextrins; 
2. To evaluate the effect of pH and temperature on the 
complexation of some drugs with cyclodextrins and to 
estimate the thermodynamic characteristiscs of the system 
at various conditions; 
3 . To develop a mathematical model using non-linear 
regression to calculate enthalpy and entropy of 
complexation; 
4. To evaluate the potential use of a new ~ cyclodextrin 
10 
derivative as a complexing agent; 
5. To investigate the properties of ~ cyclodextrin as an 
additive in tablet formulation. 
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Figure 1 
Schematic representation of the formation 
of cyclodextrin inclusion complexes 
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Figure 2 
Schematic representation of the thermodynamic process 
of drug:cyclodextrin complexation 
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The molecular encapsulation of pharmaceutical 
substances by cyclodextrins has been shown to enhance the 
solubility and the dissolution of a drug (1,2), to decrease 
drug degradation (3) and to improve the absorption from the 
gastro-intestinal tract (4) and through the skin (5). 
Phenytoin, a widely used anticonvulsant, has a low aqueous 
solubility and follows non linear pharmacokinetics (6). A 
coprecipitate of phenytoin with polyvinylpyrrolidone has 
been shown to produce a significant increase in the drug 
dissolution rate (7). Phenytoin has been reported to 
interact with beta cyclodextrin and to form a 1:1 complex 
(8). The complexation of phenytoin with cyclodextrins could 
improve solubility and dissolution rate of the drug as well 
as decrease the intra- and inter-variability of the 
absorption in patients. 
Numerous publications in the field of drug / cyclodextrin 
complexation describe briefly studies of the complexation by 
the solubility method, but do not always indicate the exact 
19 
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conditions of the experiments (pH, ionic strength of the 
solutions). Few published studies are actually focused on 
the physico-chemical aspects of the complexation of drugs 
with cyclodextrins. The objective of the study was to 
investigate the effect of temperature and pH on the 
thermodynamics of the complexation , and to propose a model 
of the complexation mechanism, describing how both the 
unionized and the ionized forms of phenytoin interact with 
cyclodextrins. 
EXPERIMENTAL 
Materials 
Phenytoina and alpha,beta and gamma cyclodextrinsb were 
used as received. All other reagents or solvents were of 
analytical grade. Deionized water was used to prepare all 
buffer solutions, which were adjusted to an ionic strength 
of 0 . 3 using potassium chloride. 
Methods 
Ultra-Violet analysis of phenytoin. Phenytoin was 
assayed using a Hewlett-Packard HP 8451A diode array 
Ultra- Violet spectrophotometer at a wavelength of 225nm. The 
Beer-Lambert law was obeyed and the molar absorptivity at 
225nm was found to be 6.72 x 10 3 . 
aUSP grade. Sigma Chemical Co., St. Louis, MO. 
bAmerican Maize, Hammond, IN. 
2n 
pKa determination. The pKa of phenytoin was determined 
from the solubility data using the Benet approach (9). 
Solubility studies. The solubility method described by 
Higuchi and Lach (10) was used under different pH and 
temperature conditions. An excess of phenytoin was placed 
into screw-capped vials containing solutions of 
cyclodextrins at various concentrations. The vials were 
shaken using a rotating unit in a controlled temperature (+ 
o.1°c) waterbath. The time needed to reach equilibrium was 
determined to be about four hours. The samples were then 
pipetted, filtered through glass wool and diluted before 
being analyzed to determine the total concentration of 
phenytoin. All sampling, filtration and dilution steps were 
carried out in a constant temperature walk-in oven. 
RESULTS AND DISCUSSION 
pKa determination 
The solubility of phenytoin as a function of pH is 
shown in Figure 1. From the plot shown in Figure 2, the 
value of pKa was determined to be 8.2, which is in good 
agreement with the literature values (11,12). 
Heat of solution 
The solubility of phenytoin was determined at different 
temperatures. The Van't Hoff equation gives a relationship 
between the solubility expressed in mole fraction and the 
absolute temperature for and ideal solution: 
21 
-log Xi ( 6Hf I RT ) + constant 
where Xi is the molar solubility in mole fraction 
6Hf is the heat of solution 
R is the constant o f perfect gases 
and T is the absolute temperature 
( 1) 
Table 1 shows the values of the heat of solution at 
different pH values. As pH increases, the heat of solution 
decreases, showing that the ionized form of phenytoin needs 
less energy to go into solution. 
Effect of ring size 
The solubility measurements were carried out using three 
cyclodextrins viz alpha, beta and gamma. Figure 3 shows the 
solubility isotherms of phenytoin with the three 
cyclodextrins at 2s0 c. Phenytoin interacts with alpha and 
gamma cyclodextrins, but to a much lesser extent than with 
beta cyclodextrin. According to the Higuchi and Lach 
approach (10), and assuming the formation of a 1:1 complex, 
the apparent thermodynamic constant of complexation could be 
calculated from the slope and the intercept of the straight 
lines obtained in Figure 3. 
K Sl I I (1-Sl) ( 2) 
where K is the apparent thermodynamic constant 
22 
Sl is the slope of the solubility isotherm 
and I is the intercept of the solubility isotherm 
The values of the complexation constants were 
-1 -1 -1 0 determined to be 110 M , 850 M and 149 M at 25 C and pH 
7 for alpha, beta and gamma cyclodextrins respectively. 
Effect of temperature 
Figure 4 shows the plot of the solubility of phenytoin 
as a function of cyclodextrin concentration at temperatures 
ranging from 20°c to 5o0 c and pH 5. At each temperature, the 
apparent complexation constant was calculated using equation 
(2). The apparent change in free energy N3 was then computed 
from the following equation: 
- R T ln K ( 3) 
The thermodynamic parame~ers of complexation were 
determined using the Gibbs equation: 
AG T AS ( 4) 
Figure 5 shows the plot of AG as a function of T at pH 
5. The slope and the intercept correspond to the entropy 
(AS) and the enthalpy (AH) of complexation respectively. 
Effect of pH 
23 
Figure 6 shows the solubility isotherms of 
phenytoin/ cyclodextrin complexation at various pH values. 
From the straight lines obtained, the apparent values of the 
complexation constant and the free energy were determined 
and are shown in Table 2 at a giv en temperature of 20°c. As 
pH increased the slope value increased showing that the 
ionized form of the drug does interact with beta 
cyclodextrin. However the interaction of the ionized form is 
weaker than for the unionized species. 
The same experiment was perf.ormed at different 
temperatures. Table 3 shows the values of the overall 
entropy and enthalpy of complexation, calculated from the 
Van't Hoff plots, similar to that shown in Figure 5. The 
values in Table 3 are actually the geometric mean of the 
indiv idual thermodynamic parameters describing the 
complexation for both the unionized and the ionized forms of 
phenytoin. 
As pH increased, the intercept of the straight lines 
shown in Figure 6 increased, due to the ionization of 
phenytoin, which has a pKa of 8.3. However, as pH increased, 
the slope of the solubility isotherms also increased, 
clearly demonstrating a further increase of the total 
phenytoin concentration as shown in Figure 7. 
The following model was developed to describe the 
complexation process: 
24 
Ki ( 6) 
where Ku and Ki are the apparent thermodynamic 
complexation constants for the unionized and ionized forms 
of phenytoin respectively . (CD)u and (CD)i correspond to 
the free cyclodextrin concentration at pH 5 and pH>7 
respectively. 
At any pH value, the total concentration of phenytoin 
and cyclodextrin, respectively noted (Phenytoin)t and (CD)t, 
can be expressed as: 
(Phenytoin)t (7) 
(CD)t (CD)i + (AH/ CD) + (A- / CD) ( 8) 
By substituting at any given temperature one set of 
data (pH 5) from another (pH>7), it is possible to obtain a 
plot of (A-)+(A- / CD) a.s a function of (CD)t, as shown in 
Figure 8. The intercept corresponds to the concentration of 
the ionized species of phenytoin, and the slope can be 
written as: 
slope (A- / CD) I (CD)t 
By combining equations (7), (8) and (9): 
slope Ki (A-) (CD)i I (CD)i + Ku (AH) (CD)u 
+ Ki (A-) (CD)i 
( 9) 
( 1 0 ) 
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The expression Ku (AH) (CD) corresponds to (AH/ CD) at pH 
5. The concentration of the free cyclodextrin varies with 
pH, but can be expressed as a function of (CD)u at pH 5, 
according to the following equation: 
(CD)i r (CD)u (ll) 
where r is the proportionality factor between (CD)i 
and (CD)u. 
Therefore, at pH>7: 
slope ( 12) 
AH and A- represent the intercepts shown in Figure 6. 
AH is the intercept (I) at pH 5, and A is the intercept 
(I-) at pH>7. 
If Sl represents the slope of the solubility isotherm 
at pH 7: 
Sl Ki I r / ( r + Ku I + Ki I r ) (13) 
r Sl + Ku I Sl + Ki I r Sl Ki I r (14) 
Ki Sl ( r + Ku I ) ) I ( I r (1 - Sl ) ) (15) 
Equation 15 allows for the determination of the 
apparent complexation constant of the ionized form of 
phenytoin with beta cyclodextrin. 
The apparent values of the complexation constant (Ki) 
and the free energy (~Gil were computed at different 
temperatures, and the Gibbs equation was used to determine 
the enthalpy (AHi) and entropy (ASi) of the ionized species 
of phenytoin with beta cyclodextrin. 
The values are reported in Table 3. The coefficient of 
correlation of the linear plot obtained at pH 5 was high 
(r=0.966 in Figure 5) . However, in the case of the 
complexation of the ionized spec ies with beta cyclodextrin, 
the coefficient of correlation was lower (from r=0.8 to 
r=0.6). The relatively poor correlation is probably due to 
the noise in the experimental values and to the fact that 
the data used for the plots from pH 7 to pH 10 were obtained 
by substraction of one set of data from another. Thus, the 
thermodynamic parameters obtained for the ionized species, 
since they are derived from two sets of experimental data, 
have the potent i al of twice as much an experimental error 
than in the case of the unionized species . At pH 7 and pH 8, 
the plot was linear at a 90% confidence level. The use of a 
computerized approach, providing a more precise 
determination of the thermodynamic parameters together with 
the exact standard deviation of the values, would allow a 
more extensive discus s ion of the results. 
SUMMARY 
Phenytoin interacts much more strongly with beta 
cyclodextrin than with alpha or gamma cyclodextrins. This 
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result is in accordance with previously reported work, 
indicating that geometric parameters play a major role in 
controlling the mechanism of complexation (the hand in glove 
theory). 
The study at various pH values shows that both the 
non-ionized and the ionized forms of phenytoin interact with 
cyclodextrins. If the purely geometric consideration were to 
be confirmed, the ionized species should either not interact 
at all, or interact to the same extent. The ionized form of 
phenytoin is shown here to interact to a much lesser extent, 
suggesting that some chemical parameters are involved in the 
complexation. 
There are a few examples in the literature show the 
interaction of both species (15-18) . The possible 
delocalization of electrons or the influence of the energy 
of salvation have been proposed but no definite explanation 
has been established. 
The biopharmaceutical implications of the interaction 
of cyclodextrins with both species are quite significant. 
For an orally administered dosage form of the complex, the 
change of pH through the gastro-intestinal tract will 
eventually lead to a different overall amount of bound drug, 
with a clear effect on the bioavailability of the drug. For 
an intravenous injection, the dissociation of the complex 
would occur at pH 7.2 to 7.6. The assumption of a solely 
unionized form of the bound drug to cyclodextrin with both 
the unionized and the ionized forms free would then create 
29 
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an error in the results. For any type of interaction, 
Riegelman described the free drug as the activity factor and 
the bound drug as the capacity factor. The possible 
complexation of the ionized species with cyclodextrins in an 
intravenous solution would actually decrease the amount of 
free drug, but would also increase the amount of bound drug, 
therefore increasing the effective overall biological 
half-life. 
ACKNOWLEDGEMENTS 
The authors are grateful to Miles Pharmaceuticals for 
financial support in the study, and American Maize for 
providing the cyclodextrin materials. 
REFERENCES 
1 . D.D. Chow and A.O. Kanara. Int. J. Pharmaceutics. 28, 
95-101 ( 1986). 
2 . K. Uekama, F. Hirayama, A. Fujise, M. Otagiri, K. Inaba 
and H Saito. J. Pharm. Sci. 73 (3), 382-384 (1984). 
3. P. Hsyu, R.P. Hegde, B.K. Birmingham and C.T. Rhodes. 
Drug DEv. Ind. Pharm. 10 (4), 601-611 (1984). 
4. T. Tokumura, Y. Tsushima, K. Tatsuishi, M. Kayano, Y. 
Machida and T. Nagai. Chem.Pharm.Bull. 33 (7), 2962-2967 
( 1985). 
5. K. Uekama, M. Otagiri, s. Sakai, T. Irie, N. Matsuo and 
Y. Matsuoka. J.Pharm.Pharmacol. 37 (8), 532 -535 (1985). 
6 . E. Martin, T.N. Tozer, L.B. Sheiner and S. Riegelman. J. 
Pharmacokinetics Biopharm. 5 (6), 579 - 598 (1977). 
7. s. Yakou, s. Yamasaki, T. Sonobe, T. nagai and M. 
Sughihara. Chem.Pharm.Bull. 34 (8), 3408-3414 (1986). 
30 
( 
8. R.P. Hegde and C . T. Rhodes. Pharrn . Act . Helv . 6 (53), 
(1985). 
9. c.c. Peck and L . Z. Benet. J . Pharrn.Sci. 67 (1), 12-16 
(1978). 
10. T. Higuchi and J.L. Lach. J.Arn.Pharrn.Assoc. 43, 349 
(1954). 
11. P . A. Schwartz, C.T . Rhodes and J.W . Cooper. J.Pharrn.Sci. 
66, 994-997 (1977). 
12. S.P. Agarwal and M.I. Blake. J.Pharrn.Sci. 57 (8), 
1434-1435 (1968). 
13. R.L. VanEtten, J . F. Sebastian, G.A. Clowes and M.L. 
Bender. J . Arn.Chern.Soc. 89 (13), 3242-3262 (1967). 
14. B . Siegel and R . Breslow. J .Arn. Chern .Soc . 97 (23), 
6869-6970 (1975) . 
15. T.K. Korpela and J.-P. Hirnanen . J . Chrornatogr . 290, 
351 - 361 (1984). 
16. R.J. Bergeron, M.A. Channing and K.A. McGovern. 
J.Arn.Chern.Soc. 100 (9), 2878 - 2883 (1978) . 
17. K. A. Connors and J.M . Lipari. J.Pharrn.Sci. 65 (3), 
379 -383 (1976) . 
18. K. Uekarna, F. Hirayama, s . Nasu, N. Matsuo and T. Irie. 
Chern.Pharrn. Bull. 26 (11), 3477-3484 (1978) . 
31 
"rable 1 
Apparent heat of solution of phenytoin 
at various pH values 
pH 
5 
7 
8 
9 
6 Hf (Kcal/mole) 
4.208 
4.224 
3 .329 
2.325 
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Table 2 
Apparent values of the complexation constant 
and the free energy of complexation for phenytoin 
and beta cyclodextrin at 20°c 
pH K (M-') l>G (Kcal/mole) l>G (KJ/mole) 
5 847.9 - 3.93 - 16.43 
7 923.9 - 3.98 
-
16.64 
8 695.9 - 3.82 - 15.97 
9 277. 0 
-
3.28 - l3. 71 
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Table 3 
Enthalpy and entropy values for the 
complexation of phenytoin (ionized and unionized) 
with beta cyclodextrin at various pHs 
pH 7 pH 8 pH 9 pH 10 
t. Hi (Kcal/mole) - 5.0 - 6.3 - 7.3 - 5.5 
t. Si ( cal/mole/K) - 5. 0 - 9 . 7 -14.0 - 9.8 
pH 5 
t.Hu (kcal/mole) - 9.1 
t.Su (cal/mole/Kl -16.0 
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Figure 1 
Solubility profile of phenytoin at 2s 0 c 
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Plot of log (S / So - 1) VS 
~7 
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Figure 3 
Complexation of phenytoin with a, 13 and ll" cyclodextrins 
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Figure 4 
Complexation of phenytoin with ~ cyclodextrin at pH 5 
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Determination of the overall enthalpy and entropy 
for the complexation of phenytoin with ~ cyclodextrin 
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Effect of pH on the complexation ob phenytoin 
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un = non-ionized 
The lines noted un are parallel to the pH 5 solubility 
isotherm 
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MANUSCRIPT II 
ABSTRACT 
A new computer method was proposed to calculate the 
thermodynamic parameters of drug / cyclodextrin complexation. 
The method allowed the simultaneous determination of two or 
more parameters using non-linear regression. The 
mathematical model was developed and used to obtain the 
estimates of enthalpy, entropy and solubility parameters. 
The output of the NONLIN program also provided the value of 
the standard deviation of the parameters, thus allowing 
meaningful comparisons between different systems. 
Key words: Non-linear regression, Thermodynamics, Phenytoin, 
Cyclodextrin, Complexation. 
52 
Determination of Thermodynamic Parameters of Complexation 
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INTRODUCTION 
The complexation of pharmaceutical substances with 
cyclodextrins has been shown to improve stability (1,2), 
solubility (2), dissolution rate (3) and bioavailability 
properties (4) . The physico-chemical aspect of the 
complexation phenomenon and especially the determination of 
the thermodynamic parameters of complexation are essential 
to characterize the drug/cyclodextrin interaction. 
Different methods have been suggested for the determination 
of the values of both the enthalpy and the entropy of 
complexation (5). The microcalorimetric method has the 
advantage of using direct calorimetric measurements and has 
been proposed as the most reliable method (6). However, 
this method is not always readily available in the 
laboratory and requires specific expertise (7). Another 
widely used method is based on the temperature dependence of 
the complexation constant (8). The complexation constant 
and the free energy can be determined from solubility data 
53 
using the Higuchi and Connors equation. After constructing 
the solubility isotherms at different temperatures, the 
enthalpy and entropy of complexation can be obtained from 
the plot of the free energy as a function of the absolute 
temperature. The major limitation of the temperature 
dependence method is the lack of precision of the 
thermodynamic parameters (9). The two successive steps 
requiring the use of linear regression really introduce an 
error, which can be critical in the comparison process of 
the parameters. The purpose of this paper is to present a 
novel computerized method allowing the direct treatment of 
the raw experimental data to determine the thermodynamic 
parameters of the drug / cyclodextrin complexation using 
non-linear regression. A similar approach has already been 
used by Dr. Fung for the determination of a single parameter 
viz the energy of activation from raw experimental data of 
drug stability (10). In this paper we describe a method of 
general applicability for the simultaneous determination of 
two or more parameters. 
THEORY 
The first step is to develop a mathematical model, 
which describes the relationship between the concentration 
of the drug, the concentration of cyclodextrin (CD) and 
temperature (T). The drug noted AH will be used as the 
model molecule interacting with cyclodextrins. The drug is 
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subject to ionization, but will be assumed to be in its 
non-ionized form in the first part of the paper. 
Based on a 1:1 stoichiometric ratio, the complexation 
reaction can be written as follows: 
AH + CD ~ AH / CD ( 1 ) 
The overall complexation constant K is expressed as: 
K = [AH / CD] I [AH]f [CD]f ( 2 ) 
where the notation f describes the free concentration . 
It is possible to express the apparent free energy of 
complexation AG using the relationship: 
where: 
AG = -R T ln K 
T is the absolute temperature (K) 
and R is the gas constant 
( 3) 
The Gibbs equation shows the relationship between free 
energy (AG), enthalpy (AH) and entropy (LIS) of complexation: 
AG = AH - T AS ( 4) 
The overall complexation constant K can be expressed, 
after rearrangement of equations (3) and (4) as: 
with A 
AH / RT - AS/R 
K = e 
AH / RT - AS / R 
( 5) 
A typical plot of solubility data for the drug / CD 
interaction is shown in Fig. 1. The total concentration of 
drug is plotted versus the t o tal cyclodextrin concentration. 
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The intercept of the straight line with the y-axis 
corresponds to the concentration of the free drug molecule, 
whereas the increase of the drug concentration represents 
the concentration of the complexed form. 
The following equations can be written to ascribe the 
total concentration of both the drug and the complexing 
molecule: 
(AH)t 
(CD)t 
(AH)f + (AH/ CD) 
[CD)f + (AH/ CD) 
( 6) 
(7) 
where the notation t stands for total concentration 
From Eq. (6): (AH/ CD)= [AH)t - (AH)f 
From Eq. (7) (8): (CD)f = (CD)t - [AH)t + (AH)f 
( 8) 
(9) 
By substituting (AH/ CD), [AH)f and (CD)f in Equation (2): 
K = (AH)t - (AH)f I (AH)f ( (CD)t - (AH)t + (AH)o ) (10) 
The term (AH]f, which is the free guest concentration, 
represents the actual solubility of the guest molecule, 
which varies with temperature according to the Hildebrand 
equation: 
-ln (AH)f = AHf (To-T) / R T To + ln 1f (11) 
Eq. (11) can be rearranged, and (AH)f is then expressed as: 
[AH)f= e 
t.Hf (T-To) / R T To - ln lf 
where: AHf 
T 
To 
'lS' 
eB 
heat of solution 
absolute temperature 
melting point 
activity coefficient 
( 1 2 ) 
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R constant of perfect gases 
The term B can be written as: 
B = liHf(T-To) / R T To ln 'Ir 
Eq. (10) can then be arranged according to Higuchi and 
Connors, as: 
[AH]t K [ AH] f / ( 1 + K [ AH ]f ) [ CD] t + [AH] f (13) 
The terms K and [AH]f can be substituted by the exponential 
expression, and eq. (13) now becomes: 
[AH]t = eA eB I (1 + eA eB) [CD]t + eB (14) 
or: 
[AH]t = eA+B I (l+eA+Bl [CD]t + eB ( 15) 
Eq. (15) fully describes the relationship between the total 
concentration of the drug (the dependent variable), the 
total concentration of cyclodextrin (the first independent 
variable) and the absolute temperature (the second 
independent variable), which is included in the expression 
of both terms A and B. 
A and B also include the thermodynamic parameters of 
complexation (6H and 4S) and the free guest solubility 
parameters (6Hf and ln~ ), respectively. 
Eq. (15) will be used as the mathematical model, 
allowing for the direct treatment of the raw experimental 
data. Eq. (15) can therefore be applied to any type of 
interaction, in which the stoichiometric ratio complexation 
is known to be 1:1. 
In the case of the complexation of phenytoin with ~ 
cyclodextrin, some previously published work has shown that 
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the stoichiometry of the complex is indeed 1:1 (11). This 
result was obtained after preparation of the freeze-dried 
form of the complex and analysis using X-Ray, PMN and DSC 
(12). 
Figure 2 shows a typical solubility isotherm at pH >7 
together with that at pH 5. Assuming that the complexing 
ability of cyclodextrins is pH-independent, the further 
increase of the slope corresponds to the complexation of the 
ionized form of the drug with ~ cyclodextrin. 
Phenytoin is a weak acid, with a pKa of 8.3 (13,14), 
and has already been reported to interact with ~ 
cyclodextrin both as the non-ionized and as the ionized 
forms (9). At low pH values (pH 5), phenytoin is non-
ionized, and Eq. (15) can be applied to study the 
complexation phenomenon from the solubility data. However, 
at higher pH values, the complexation of the ionized species 
with ~ cyclodextrin has to be taken into consideration. An 
extension to the model is thus needed. 
The symbols used in the development of the equations 
will take into consideration both complexation phenomena. 
If AH represents the non-ionized form of the drug and A the 
ionized species, the different equations can be written as 
follows: 
non-ionized species ionized species 
pH 5 pH >7 
( 16) 
AH + CD ~ AH / CD 
Ku=[AH / CD) / [AH)uf[CD)f 
AGU= - R T ln Ku 
Ki =[A- / CD) / [A-Jif[CD)if 
AGi= 
- R T ln Ki 
AGu= AHu - T Su llGi= ti Hi 
-
T t.Si 
ln[AH)= Hfu(T-To) / RTTo-ln¥u 
Eq. (14) has already been developed: 
[AH]ut = (eAu+Bu) I (l+eAu+Bu) [CD)t + eBu 
The intercept of the solubility isotherm at pH 7 can be 
expressed as: 
( 24) 
or 
or 
The total drug concentration [AH)t can be written: 
[AH)it = [AH)u + [AH/ CD)u + [A-)if + [A- / CD)i 
[AH]it= [AH)ut + (Ii-Iu) + [A- / CD)i 
and: [A- / CD)i=[AH]it-[AH)ut-[Ii-Iu) 
[AH/ CD]u = [AH]ut- Iu 
The total cyclodextrin concentration [CD)t can be 
written as: 
or 
( 17) 
( 18) 
( 19) 
( 20) 
( 21) 
( 15) 
( 22) 
( 23) 
( 25) 
( 26) 
(8) 
( 27) 
( 28) 
s ~ 
The apparent complexation constant Ki under the current 
conditions can then be expressed as: 
Ki= [A- / CD]i I [A-]if [CD]if ( 18) 
Ki=([AH]it-[AH]ut-(Ii-Iu)) / (Ii-Iu)([CD]it-(AH/ CD]u-[A- / CD]i) 
( 29) 
ki=([AH]it - (AH)ut-(Ii-Iu)) / (Ii-Iu)([CD]it-((AH]ut-Iu)-
([AH)it-[AH]ut - (Ii-Iu)) (30) 
[AH]it- [AH]ut-(Ii-Iu)=Ki(Ii-Iu)([CD)it-([AH)it-[AH]ut-
After rearrangement: 
(Ii-Iu))-([AH]ut-Iu)) 
(Kili-Kilu)([CD]it-[AH]it+Ii) 
[AH]it= (Kiii-Kiiu) / (l+Kii-Kiu) [CD]it + [AH]it + 
( 31) 
( 32) 
(Ii-Iu) (l+Kili) (33) 
Equation (33) shows the relations hip between the total 
drug concentration at pH>7 (the dependent variable), the 
total cyclodextrin concentration (the first independent 
variable) and the temperature, at which the complexation 
occurs (the second independent variable) . 
The terms Iu and [AH)ut correspond to the free drug 
concentration and the total drug concentration at pH 5, 
respectively. Since the complexation ability of 
cyclodextrin is assumed to remain constant through the pH 
range studied, Iu and [AH]ut remain constant. 
COMPUTER TREATMENT OF DATA 
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The experimental data treated using the novel computer 
method have been published previously (9). The lack of 
precision of the thermodynamic parameters was the main 
limitation of the results, thus an extensive discussion of 
the thermodynamics of complexation was rather difficult. 
The NONLIN computer program was used to determine the 
final estimates of all thermodynamic parameters. The NONLIN 
regression approach has been sucessfully used to determine 
parameters in many fields such as pharmacokinetics (15) and 
protein binding (16). The different programs needed to 
treat the data were: 
1) the datafile, which included all the experimental data, 
the initial estimates and the limits of the parameters; 
2) the subroutine program consisting of the declaration of 
the different variables and the full mathematical model 
describing the complexation; 
3) a link program, which allows for the iterations of the 
NONLIN program to take place and the data to be called in. 
The method of determining the parameters using the 
NONLIN computer was validated by running a set of simulated 
data. The simulated data were obtained by giving a specific 
value to each of the parameters appearing in eq. 15. The 
enthalpy and the entropy of complexation were assigned a 
value of -10.0 Kcal.mol-l and -10.0 eu respectively. The 
solubility parameters used were 15.0 Kcal mol-l for the heat 
of solution and 5.0 for the activity coefficient. All the 
concentrations were rounded to two significant digits. 
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The schematic representation of the programs used is 
shown in Figure 3. Eq. (15) corresponds to the complexation 
at pH 5 of the unionized species, whereas Eq. (33) fits the 
data obtained when both species form a complex. For a set 
of data at pH>7, the subroutine program was designed so that 
the complexation occurring between the unionized species and 
the ~ cyclodextrin was taken into account. Thus, for each 
temperature and at each cyclodextrin concentration, the 
program regenerated the drug concentrations calculated at pH 
5, based on the previous determination of 6Hu and 6Su. 
RESULTS AND DISCUSSION 
Validation of the program 
The datafile created from the set of simulated data was 
run with a subroutine program allowing the determination of 
the four unknown values, namely enthalpy, entropy, heat of 
solution and activity coefficient. The NONLIN program 
converged to the values shown in Table 1. The values 
determined by the computer were in excellent agreement with 
the theoretical values. The results clearly show that this 
method is perfectly applicable for the determination of four 
unknown values from a set of 24 concentrations; in this case 
four temperatures and six cyclodextrin concentrations. 
Advantages and general application of the method 
All the equations, such as the expression of the 
equilibrium complexation constant and the Gibbs equation, 
are already included in the general equation; there is thus 
no need of the successive preliminary plots to determine the 
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thermodynamic parameters of complexation. This method not 
only allows a direct treatment of the raw experimental data, 
but also gives a clear indication of the statistical 
significance and the level of confidence associated with the 
determined parameters. 
Although the method has been developed for the case of 
the complexation of drugs with cyclodextrins, as far as the 
major assumptions of the model remain acceptable, this 
method is applicable to many other cases of drug interaction 
or molecular recognition. 
Characterization of the phenytoin/@CD interaction 
Since our objective was to evaluate the effect of pH on 
the interaction of phenytoin with a cyclodextrin, a typical 
set of data consisted of a set of phenytoin concentrations 
(independent variable) as a function of a cyclodextrin 
concentration and temperature (dependent variables). Six 
levels of a cyclodextrin concentrations and four levels of 
temperatures were used to build a database of 24 points at 
different pH values from pH 5 to pH 10. 
Table 2 shows the values of the overall thermodynamic 
parameters determined using the NONLIN program, at different 
pH values. The enthalpies and entropies actually represent 
the geometric means for the complexation of both the 
non-ionized and the ionized species of phenytoin with a 
cyclodextrin. As pH increases, the relative standard of 
deviation increases, probably due to the much higher 
concentrations of phenytoin at pH 9 or 10 compared to those 
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at pH 5, when the drug is non ionized. The large negative 
values of enthalpy suggest a strong dipole interaction, 
either due to the interaction between the drug and the 
cyclodextrins or due to the change of behavior of the water 
molecules associated with both the drug and the 
cyclodextrin. The negative entropies suggest that the 
solvent has a more ordered structure after complex 
formation. At this point, it is difficult to be more 
specific, since the values in Table 2 are not exclusively 
related to either form of the drug, but rather represent an 
overall estimate of the thermodynamic changes occurring 
during the formation of the phenytoin/ ~ cyclodextrin 
complex. 
In order to further analyze the results, the more 
sophisticated mathematical model described in eq. (33) had 
to be used . In order to run the subroutine program for 
datafiles at pH>7, the respective values -9,714.9 cal.mol-l 
and -10.49 e.u. were used for the enthalpy and the entropy 
of complexation of the unionized form of phenytoin with ~ 
cyclodextrin. It is assumed that the complexation of the 
non-ionized drug with cyclodextrin is not affected by change 
in pH used in the study, which also means graphically that a 
parallel line to the pH solubility isotherm could actually 
be drawn at any pH value. The results of the treatment of 
the raw experimental data using the computer method are 
shown in Table 3. The correlation between the data and the 
theoretical model of eq. (33) was excellent with a 
64 
coefficient of correlation from 0.99 to 0.97, with 24 points 
ie. 20 degrees of freedom. 
The negative values of enthalpy show again a strong 
involvement of dipole interaction. It can be mentioned that 
the enthalpy of complexation is lower at pH 7 and pH 8, 
where the drug is only slightly ionized. The value 
increases at pH 9 and pH 10, suggesting a possible 
contribution of the charge of the ionized phenytoin 
molecule. A widely proposed theory is that the apolar and 
non-ionized drug molecule leaves behind a structured cavity, 
which allows the solvent molecules to redistribute upon 
complexation. This aspect of the mechanism is likely to 
vary as a function of pH, since the polarity of phenytoin is 
pH-dependent. The relative standard deviation is very high 
at pH 7, showing that the low percentage of ionization does 
not allow an accurate determination of AH. The values of 
entropy become large at pH 9 and pH 10, suggesting a much 
more ordered solvent after complexation. At pH 7 and pH 8, 
the standard deviations are very high, and the positive 
value of entropy probably only indicates little or even no 
entropy change. 
SUMMARY 
The new model and method introduced here allow the 
determination of more than one unknown from one set of raw 
experimental data. Even though the method was used to treat 
data from the complexation of phenytoin with cyclodextrins, 
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( the same approach could be exploited for other drug 
interaction system. The method allows for a meaningful 
comparison of thermodynamic parameters for the interaction 
of either one drug with different cyclodextrins or one 
cyclodextrin with different drugs. The use of the approach 
could enhance the ability of the pharmaceutical scientist to 
analyze data from the solubility method to propose a 
rationale of interaction between drugs and complexing 
agents. 
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Table 1 
Thermodynamic parameters of complexation determined 
from a set of simulated data 
Parameter Theoretical Final Standard 95% 
Value Estimate Deviation Conf. Limit 
Enthalpy 
AH -10,000 -10,164 60 9,959-10370 
-1 (cal.mol ) 
Entropy 
LIS -10.0 -10.55 0.19 9 . 91-11.19 
(e . u. l 
Heat 
A Hf 15,000 15,154 57 14,960-15,349 
-1 (cal.mol ) 
Activity 
ln 1l' 5.0 4.43 1.0 3 . 87-5.05 
pH 
5.0 
7.0 
8.0 
9.0 
10.0 
Table 2 
Overall enthalpies and entropies of complexation 
for the phenytoin/~cyclodextrin interaction 
-1 (Kcal.mol ) 
- 9,721 
-11, 528 
- 9,292 
- 8,802 
- 8,982 
RSD 
(%) 
1.1 
1. 2 
1. 3 
4.2 
12.9 
~s RSD 
(e.u.) (%) 
-10.49 3.3 
-16.32 2 . 8 
-10.02 3 .8 
-10.18 11. 8 
-12.44 30.5 
pH 
7.0 
8.0 
9.0 
10.0 
Table 3 
Enthalpies and entropies for the complexation 
of phenytoin ion with ~cyclodextrin 
r 
0.998 - 5,326 40.4 
0.999 - 5,352 5.8 
0.995 - 8,899 4.0 
0.973 -12,934 5.2 
Asi 
(e.u. l 
1. 68 
1. 35 
- 10.75 
- 25.41 
RSD 
( %) 
405.0 
74.0 
10.7 
8.6 
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Figure 1 
Typical solubility isotherm for the complexation 
of non- ionized phenytoin with ~ CD at pH 5 
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[CD]t 
Figure 1: Typical solubility isotherm of the complexation 
of non-ionized phenytoin with ('>Cyclodextrin at 
pH 5 
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Figure 2 
Typical solubility isotherm of phenytoin 
with ~ CD at pH >7 
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7d 
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[AH]f I I [AH]f 
~~~~~~~~~~~~~~~~~~ 
[CD]t 
Figure 2 : Typical solubility isotherm of the complexation 
of phenytoin with ~cyclodextrin at pH 7 
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Figure 3 
Schematic representation of the different programs 
DATAFILE SUBROUTINE 
Values of: [AH)t, [CD)t and T Equation (15) (pH 5) 
or Equation ( 33) (pH 7) Inital estimates for: 
CIH, AS, f.Hf and ln ~ 
~/ 
JOB CONTROL LANGUAGE 
! 
NONLIN l Iterations 
OUTPUT 
Calculated values of [AH)t 
Coefficient of correlation 
Final estimates for: AH, AS, f.Hf and lnY 
Standard deviation and 95 % confidence limits 
Figure 3: Schematic representation of the different 
programs 
7G 
77 
MANUSCRIPT I II 
Potential Pharmaceutical Applications 
of a New Beta Cyclodextrin Derivative 
aF.A. Menarda, M.G. Dedhiyab and C.T. Rhodesa 
Department of Pharmaceutics 
bUniversity of Rhode Island Kingston RI 02881 - 0809 
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INTRODUCTION 
The three major natural cyclodextrins viz alpha, beta 
and gamma, consist of six, seven or eight glucose units, 
respectively (1). In addition to the natural cyclodextrins, 
numerous new products have been shown to have potential for 
the pharmaceutical industry (2,3). A clear distinction has 
to be made between cyclodextrin polymers, which are mainly 
used as separation materials in analytical chemistry (4) and 
cyclodextrin derivatives, which are monomers of substituted 
cyclodextrins (5). In the synthesis process of the latter, 
both the C(2) and C(3) secondary and the C(6) primary 
hydroxyl groups have been the target of many chemical 
substitutions (6), leading to the development and the 
characterization of cyclodextrin derivatives of 
pharmaceutical interest (7). Such derivatives have been 
successfully used in the design of new drug carrier systems 
(3,5). Hence, in addition to their increased solubility, 
these chemically modified cyclodextrins exhibit excellent 
complexing abilities (8). The different possibilities of 
modifying cyclodextrins have been reviewed by Sebille (2), 
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Szejtli (1) and Uekama (3). Szjetli also published an 
extensive list of the major cyclodextrin derivatives under 
investigation until 1982 (1). 
The chemical considerations of the substitution of 
cyclodextrins have been investigated by Harata et al., who 
examined the macrolytic conformation of permethylated 
cyclodextrins (6). The main factor is the loss of the 
ability to form hydrogen bonds upon substitution. Further 
studies dealing with the properties of cyclodextrin 
derivatives have been recently published (9). 
The stability of prostaglandins was improved by 
complexation with methylated cyclodextrins (10). On the 
other hand, an ammonium beta cyclodextrin derivative was 
shown to catalyze the hydrolysis of nitrophenyl ester (11). 
Nakai et al. studied the effect of a tri-methyl beta 
cyclodextrin on the partition of nitrophenol, and 
interpreted the data as the formation of a 1:1 complex (12). 
The use of cyclodextrin derivatives as agents of 
solubilization has been reported in the literature (13). 
Muller and Brauns have investigated the complexation of 
diazepam, hydrocortisone and digitoxin with methyl beta 
cyclodextrin (14), as well as the effect of the 
derivatization of gamma cyclodextrin on the phase-solubility 
of progesterone (15). Otagiri et al. have also studied the 
complexation of several drugs with tri-methyl cyclodextrin. 
In most of the studies, the critical factor to be carefully 
considered in the interpretation of the data is the degree 
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of substitution (DS) of the cyclodextrin derivatives (16). 
Muller and Brauns have established a relationship between 
the average degree of substitution and the complexing 
ability (14) . From the data obtained, the lower the degree 
of substitution, the more extensive the complexation 
phenomenon. This result was attributed to the steric 
blockage of the cyclodextrin cavity by the substituents. 
Several researchers have published data regarding 
specific dosage forms of complexes of drug / cyclodextrin 
derivatives. Dimethyl beta cyclodextrin has been proposed 
as a parenteral drug carrier for such drugs as progesterone 
and hydrocortisone (17). The dissolution of flurbiprofen 
suppositories was shown to be greatly improved by 
complexation with dimethyl and trimethyl beta cyclodextrin 
(18). Also, a comparative study of the complexation of 
flurbiprofen with both beta cyclodextrin and its derivatives 
showed that the mode of inclusion was quite different, due 
to the different number of free hydroxyl groups on the 
cyclodextrin ring (18) . In-vivo studies in rats suggested 
that the complexation of ketoprofen with methyl beta 
cyclodextrin could lead to high plasma levels (19). It was 
also proposed that the surface active properties of methyl 
beta cyclodextrins could facilitate drug absorption through 
membranes. However, as discussed further in this paper, the 
same surface active properties may well be responsible for 
negative toxic effects on the cells, causing hemolysis (3). 
Pitha et al . investigated the oral administration of 
an 
steroidal hormones. The study showed that the complexation 
of progesterone and testosterone with beta cyclodextrin 
derivatives allowed for the correction of serum levels and 
could efficiently be used for therapeutic applications (17). 
Even though the hydrophilic cyclodextrins have been the 
focus of the attention of many researchers, Uekama recently 
published data showing that ethylated beta cyclodextrins 
could be used as hydrophobic drug carriers. An in-vivo 
study in rats showed that these hydrophobic derivatives 
produced a sustained release of diltiazem (21). It is very 
likely that more work will be done in the future to 
establish the exact potential of cyclodextrin derivatives in 
sustained release. 
The purpose of this paper is to evaluate the complexing 
ability of hydroxyethyl beta cyclodextrin, a new beta 
cyclodextrin derivative. Furthermore, the complexation of 
several drugs with both the natural beta cyclodextrin and 
its new derivative was investigated in order to establish a 
possible comparison of the data and to propose a valid 
prediction of the overall increase in drug solubility upon 
complexation. 
EXPERIMENTAL 
Materials 
Hydroxyethyl beta cyclodextrin (batch #CDM108) was 
obtained from American Maize (Hammond, IN). Table 1 shows 
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some of its basic physico-chemical properties, compared to 
those of the natural cyclodextrins. 
Three of the drugs viz phenytoin, diazepam and 
hydrochlorothiazide were obtained from Sigma Chemical Co. 
(St. Louis, MO). Ibuprofen was generously given by 
Whitehall Laboratories. All drugs were used as received. 
All solvents and reagents used in the study were of 
analytical grade and were used as received. 
Methodology 
The complexation of the drugs with the new modified 
beta cyclodextrin was studied using the solubility method 
described by Higuchi and Connors (21). An excess of drug 
was placed into screw-capped vials containing various 
concentrations of cyclodextrins. The vials were then 
rotated at constant temperature (±o.os0 c) in a waterbath, 
until the maximum solubility was reached. The samples of 
drug solutions were then filtered using glasswool, diluted 
and assayed for drug concentration using a diode-array 
ultra-violet spectrophotometer (Hewlett-Packard HP 8451A). 
The drug standards obeyed the Beer's law in all cases, and 
cyclodextrin was shown not to interfere with the assay. 
RESULTS AND DISCUSSION 
The solubility isotherms were obtained by plotting 
the total drug concentration as a function of total 
cyclodextrin concentration. In all cases the plots were 
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linear, suggesting a type A phase solubility (21). The 
intercept represents the concentration of the free drug, 
while the slope represents the solubilization power of the 
complexing agent. Figures 1, 2, 3 and 4 show the solubility 
isotherms of phenytoin, diazepam, ibuprofen and 
hydrochlorothiazide, respectively. Each plot shows the 
complexation data with both beta cyclodextrin and the 
hydroxyethyl derivative. The maximum concentration of beta 
cyclodextrin used was 15 x 10- 3 M, except in the case of 
ibuprofen, where a maximum concentration of 5.0 x 10-3 M was 
used ,due to the low solubility of the ibuprofen/beta 
cyclodextrin complex. The concentration of hydroxyethyl 
derivative varied from 0 to about 150 x 10-3 M (20% w/ w) 
(although, according to the supplier, solutions of up to 60% 
solids could actually be prepared). The molar concentration 
was calculated using a molecular weight of 1300, value 
obtained from the average value of the degree of 
substitution. The concentrations of both complexing agents 
are plotted on the X-axis using the same scale; the use of 
the derivative thus corresponds to an extension of the 
x-axis. 
From Figures 1 to 4, it appears that the slope of the 
solubility isotherms remained identical for both complexing 
agents. This result was confirmed statistically using a SAS 
program. The results thus suggest that even though the 
overall increase of drug solubility was much higher in the 
case of the derivative, the solubilizing power was 
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unchanged. This observation confirms the "hand and glove" 
theory used to describe how the steric factors control the 
extent of complexation . Some researchers have reported that 
the complexation of drugs with cyclodextrin derivatives was 
associated with a lower solubilizing power (14 ). These 
results were obtained in the case of hydroxypropyl beta 
cyclodextrin , with high degrees of substitution. The 
decreas e of complexing ability was therefore suggested to be 
due to steric hindrance . In the case of hydroxyethyl beta 
cyclodextrin , it seems that the low degree of substitution 
presents the unique advantage of preserving the complexing 
ability of the cyclodextrin. 
The reactions of complexation can be written as 
following: 
Drug + 13 CD Drug / 13 CD 
Drug + 13'CD Drug / 13'CD 
( 1) 
( 2) 
The slope of the solubility isotherm corresponds to the 
concentration of the complexed drug over the total 
concentration of cyclodextrin, as shown in Figure 5 . 
Therefore: 
s 
S' 
[Drug / 13 CD) I [13 CD) 
[Drug/ 13'CD) I [13'CDJ 
where S and S' represent the slope for the 
complexation of drugs with 13 and 13' cyclodextrins 
respectively. 
( 3) 
( 4) 
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Assuming that the slope remains unchanged, the 
following equality can be written: 
S S' 
[Drug/~ CD) 
and 
[~ CD) 
[~'CD) 
Therefore: [Drug / ~'CD] 
[Drug / ~'CD] / [~ CD) 
10 x [~ CD] 
10 x [Drug/~ CD] 
( 5) 
( 6) 
(7) 
( 8) 
According to this model, the concentration of the 
complexed drug obtained upon complexation with the beta 
cyclodextrin derivative should be about ten times that 
observed in the case of the natural product. Both 
concentrations were calculated at different temperatures and 
at various pH values. The ratio was then computed and the 
results are reported in Table 2. The ratios are in good 
agreement with the theory; values were in the range of 8.6 
to 11.0. Two values were calculated for phenytoin and 
diazepam, since for these drugs both the ionized and the 
non-ionized species have been shown to interact with 
cyclodextrins. In the case of ibuprofen, the value was 
found to be 26.6. Once the adjustment of the concentration 
ratio is made, this value corresponds to 8.9. It should be 
mentioned that the values of concentration of complexed drug 
reported in Table 2 represent almost the total concentration 
for ibuprofen, for which the interaction is very extensive. 
However, in the case of hydrochlorothiazide, the value 
85 
represents merely half of the concentration of the free 
drug, suggesting a very weak interaction. 
A SASGRAPH software was used to plot the drug 
solubility as a function of cyclodextrin concentration and 
temperature. The three dimensional plots obtained are shown 
in Figures 6, 7, 8 and 9, for phenytoin, diazepam, ibuprofen 
and hydrochlorothiazide respectively. The overall volume of 
these plots allows a good visualization of the extent of 
complexation. 
The practical implications of the results of this study 
can be discussed at two levels. Firstly, it appears that it 
may be possible to predict the solubility of drug upon 
complexation with hydroxyethyl beta cyclodextrin, based on 
the data obtained with the natural form. Beta cyclodextrin, 
which is a much more readily available material, could be 
used as a model to evaluate whether a drug concentration in 
the range desired could be achieved through beta 
cyclodextrin derivative complexation. The empirical rule 
suggested here corresponds to the multiplication of the 
solubility observed with beta cyclodextrin by the ratio 
factor between the solubility of beta cyclodextrin and its 
derivative. This rule has been shown here to stand very 
well in the case of four drugs, at different pH values and 
different temperatures. 
The second point of interest resides in examining the 
range of solubility obtained after complexation. The 
complexation of drugs with cyclodextrins can be particularly 
86 
appropriate either to improve the physico-chemical 
properties or the organoleptic properties of drugs. 
Clearly, the concentrations of ibuprofen attained in this 
study are very high and would even make possible a liquid 
dosage form of the drug. However, ibuprofen has a bitter 
taste, that even a 60 to 70% complexation level may not 
totally mask. In the case of the other drugs, phenytoin is 
complexed at about 10% and diazeparn around 20%. This 
percentage would be a critical factor in the development of 
any dosage form of a drug/cyclodextrin complex. Obviously, 
on a development point of view, the closer to a 100% 
complexation, the better. The results of the study indicate 
that the use of hydroxyethyl beta cyclodextrin may offer 
clear advantage to the pharmaceutical formulator. 
CONCLUSIONS 
The complexation ability of ~'cyclodextrin has been 
shown to be similar to that of the natural ~ cyclodextrin. 
The slope of the solubility isotherms was indeed identical 
for the four drugs studied. It thus appears that the 
substituents do not affect the basic mechanism of 
complexation. The particular advantages of ~· cyclodextrin 
are its high solubility and its low degree of substitution. 
The range of drug concentrations achieved in the study 
suggests real new possibilities of formulation. A liquid 
dosage form of ibuprofen with high bioavailability could 
very well be developed. One of the major concerns in the 
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pharmaceutical industry has been the toxicity of the 
cyclodextrin derivatives, in particular unacceptable 
hemolytic properties. However, it has also been shown that 
the lower the degree of substitution, the lower the 
hemolytic properties. From the preformulation data 
presented here in the study, hydroxylethyl ~ cyclodextrin 
seems to be an excellent candidate for future 
drug / cyclodextrin complex formulation. 
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TABLE I 
BASIC PROPERTIES OP CYCLODEXTRIHS 
CD • GLUCOSE MW I WATER SOLUBILITY UNITS MOLECULES 9111/lOOml 
a. 6 972 6 U.5 
!'\ 7 1135 11 1.8 
~ 8 1297 17 23.2 
!'\' 7 1300 11 60.0 
DRUG 
Phenytoin 
Diazepam 
Hydrochlo-
thiazide 
Ibuprofen 
* 
TABLE II 
Concentrations of drug complexed with 
~ and ~· cyclodextrins at 50°c 
pH [DRUG]f [Drug/~CD] [Drug/~'CD] 
(mM) (mM) (mM) 
5.0 0.26 1. 28 12.69 
8.0 0.68 1. 62 13.98 
3.0 0.80 1.12 12.32 
6.0 0.29 0.71 7.82 
5.0 7.65 3.05 32.30 
5.0 0.16 0.34 9.08 
Ratio = [Drug / ~'CD) I [Drug/~CD) 
** 
* Ratio 
9.9 
8.6 
11. 0 
11.0 
10.6 
** 8.9 
The value of 8.9 was obtained by dividing 26.6 by 3 
The maximum concentration of ~ CD was 5.0 x 10- 3 M in 
the case of ibuprofen and 15.0 x 10-3 M for the other 
drugs 
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Figure I 
Complexation of phenytoin with ~ CD at 40°c and pH 5 
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Figure II 
Complexation of diazepam with ~ CD at 30°c and pH 6 
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Figure III 
Complexation of ibuprofen with ~ CD at so 0 c and pH 5 
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Figure IV 
Complexation of HCTZ with ~ CD at so0 c and pH 5 
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Figure V 
Complexation of drugs with ~ and ~· cyclodextrins 
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Figure v 
Complexation of drugs with both ~ CD and p.. 'cD 
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Figure VI 
Solubility of phenytoin as a function of 
temperature and ~· CD concentration at pH 5 
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Figure VII 
Solubility of diazepam as a function of 
temperature and ~· CD concentration at pH 6 
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Figure VIII 
Solubility of ibuprofen as a function of 
temperature and ~· CD concentration at pH 5 
106 
UJ 
I 
CL 
0 
u 
- c!C-
'-.. 
z 
w 
LI-
O 
Q:'. 
CL 
::::J 
al 
107 
Figure IX 
Solubility of hydrochlorothiazide as a function of 
temperature and ~· CD concentration at pH 5 
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MANUSCRIPT IV 
ABSTRACT 
The complexation of several drugs with beta 
cyclodextrins was studied using the Higuchi and Connors 
solubility method. Solubility isotherms were plotted for 
each drug at various pH and temperature conditions. Both 
the non-ionized and the ionized species of diazepam were 
shown to form an inclusion complex. In the case of 
ibuprofen and hydrochlorothiazide, only the non-ionized 
species interacted with beta cyclodextrin. The 
thermodynamic parameters of complexation were estimated 
using a computer method based on non-linear regression. Th e 
enthalpy of complexation was large and negative in all 
cases, while the entropy of complexation was found to depend 
more upon the nature of the drug and the experimental 
conditions . 
Key words: Cyclodextrins, complexation, thermodynamics, 
ibuprofen, diazepam, hydrochlorothiazide. 
111 
PHYSICO-CHEMICAL ASPECTS OF THE COMPLEXATION 
OF SOME DRUGS WITH CYCLODEXTRINS 
F.A. Menarda, M.G. Dedhiyab and C.T. Rhodesa 
aDepartment of Pharmaceutics 
University of Rhode Island Kingston RI 02881-0809 
bMiles Pharmaceuticals 
400 Morgan Lane West Haven CT 06516 
INTRODUCTION 
The three major cyclodextrins consist of six, seven and 
eight units of glucose, respectively (1). Cyclodextrins 
readily form inclusion complexes with a wide number of 
organic compounds. The complexation of drugs with 
cyclodextrins has been shown to have great potential for the 
pharmaceutical industry (2). The main advantages of the 
drug-cyclodextrin complex formation include: a) enhancement 
of organo-leptic properties (i.e. taste and smell); b) 
stabilization of the drug; and c) improvement of the 
solubility, dissolution and bioavailability of drugs. A 
number of papers have been published by pharmaceutical 
scientists during the last decade that focused on the 
preparation, the physical analysis and the formulation of 
drug / cyclodextrin complexes (3-7). However, the physico 
-chemical aspects of complexation have received relatively 
little attention. 
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The objectives of this paper were: to investigate the 
effect of pH and temperature on the phase-solubility of 
three drugs upon complexation with cyclodextrins and to 
determine the thermodynamic parameters of complexation using 
a novel computer approach based on a non-linear program. 
EXPERIMENTAL SECTION 
Reagents and Chemicals- All solvents and reagents were 
of analytical grade and were used as received. 
Hydrochlorothiazide and diazepam were obtained from Sigma 
Chemical Co. (St. Louis, MO). Ibuprofen was received from 
Whitehall Laboratories. The cyclodextrin materials used 
were generously offered by American Maize (Hammond, IN). 
Methods- The solubility method used was based on that 
described by Higuchi and Connors (8). An excess of solid 
drug was added into screw-capped tubes containing solutions 
of cyclodextrins at various known concentrations. The tubes 
were rotated in a waterbath at constant temperature (± 
o.os0 c) until saturation was reached. The filtration and 
dilution steps were conducted in a walk-in oven. The 
complexation of ibuprofen, diazepam and hydrochlorothiazide 
were studied at various temperatures from 20°c to so0 c, and 
at different pH values. The solubility isotherms were 
obtained by plotting the solubility of the drug as a 
function of cyclodextrin concentration. 
Computer treatment of Data- The thermodynamic 
parameters of complexation were determined using a computer 
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method based on non-linear regression. Three programs were 
used: 1) a datafile; 2) a subroutine; and 3) a JCL program 
which links the datafile and the subrouitne to the NONLIN 
software. The datafile included a full set of data 
consisting of drug concentration, cyclodextrin concentration 
and temperature at a given pH value and the initial 
estimates of the thermodynamic parameters. The three major 
parameters considered were the enthalpy ( H) and entropy 
S) of complexation, and the heat of solution ( Hs). The 
subroutine program contained the following mathematical 
equation: 
[AH)t ( 1) 
where: [AH)t 
(CD)t 
total concentration of drug in solution 
total concentration of cyclodextrin 
A ~H/RT - AS / R 
B AHs (T-To) / RTTO - lnY 
with: AH enthalpy of complexation 
AS entropy of complexation 
~Ss heat of solution 
R gas constant 
T absolute temperature (°K) 
T
0 
melting point 
~ activity coefficient 
This equation was based on the following assumptions: l)the 
stoichiometry of the drug / cyclodextrin complex was 1:1; 2) 
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the change of the free energy of complexation with 
temperature obeyed the Gibbs equation; 3) the complexing 
ability of the cyclodextrins was pH independent between pH 2 
and pH 9; and 4) the free drug solubility could be described 
by the general Van't Hoff equation. The output of the 
NONLIN program used gave the final estimates of the 
thermodynamic parameters, their standard deviation and their 
95 % confidence limits. 
Statis tical Anal ysis- An analysis of variance (ANOVA) 
was performed on the s lope of the solubility isotherms using 
a SAS statistical package . Temperature and pH were the two 
possible sources of variation. A SASGRAPH program was used 
to plot the solubility of the drug as a function of 
cyclodextrin concentration and pH. A G3D grid technique was 
used in all cases . 
RESULTS AND DI SCUSSI ON 
Determination o f pKa- The Benet and Peck approach was 
used to calculate the apparent pKa of each drug from the 
intercept data of the solubility isotherms built at a given 
temperature (9). The solubility C varies as a function of 
pH according to the following equation: 
log (C / C0 - 1) = pH - pKa ( 2) 
where C0 solubility of the unionized species 
The pKa value corresponds to the pH at which the solubility 
is twice that of the unionized species . The apparent pKa 
determined from the data available were 4.8, 3 . 6 and 8.0 for 
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ibuprofen, diazepam and hydrochlorothiazide respectively. 
These values are in good agreement with the values available 
in the literature. In the case of diazepam, which is a weak 
base, 3.6 is the pKa of the conjugated acid. 
Determination of Heat of solution- The heat of solution 
(Alis) of the free drug representes the intercept of the 
solubility isotherm. 
The Van't Hoff and Hildebrand equations can be used to 
show the solubility-temperature relationship (10). Although 
both equations have the same theoretical basis, the plot of 
the logarithm of the solubility expressed in mole fraction 
(X) as a function of the reciprocal of the absolute 
temperature is refered to as the Van't Hoff plot (11,12). 
log X -( AH / 2.303 R) (l / T) +Ct ( 3) 
The Van't Hoff plots for ibuprofen, diazepam and 
hydrochlorothiazide are shown in Figures 1, 2 and 3 
respectively. Each straight line represents a set of data 
at a given pH value. The slope of the linear plots varied 
with pH indicating that the heat absorbed by the system 
during dissolution varied with the extent of ionization. 
Table I shows the values for the heat of solution of 
the three drugs determined by both the manual method using 
equation 2 and linear regression and the computer method 
using non-linear regression. The advantage of the computer 
approach is that each parameter is estimated with a 95% 
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confidence interval. An excellent correlation was observed 
between the results obtained from the two different methods 
for all three drugs tested. In the case of ibuprofen and 
hydrochlorothiazide, which are both weak acids, an increase 
of pH resulted in lower heat of solution because of the 
increased ionization of the drug. The lack of variation in 
the Hs with pH for hydrochlorothiazide can be correlated to 
the almost parallel lines observed in Figure 3. For 
diazepam, the unionized species at pH 6 required more energy 
to go into solution. In all cases, the solubility process 
was endothermic as indicated by the positive values of heat 
of solution. 
Effect of pH on complexation- The solubility isotherms 
of the complexation of the three drugs with ~ cyclodextrin 
at various pH values and constant temperature are presented 
in Figures 4, 5 and 6. As the pH increased, the intercept 
increased for ibuprofen and hydrochlorothiazide and 
decreased for diazepam due to the ionization of the drug. 
The solubility plots obtained for diazepam (Figure 5) 
indicate that there is an increase of the slope as the pH 
decreased. Since diazepam is completely ionized at pH 2, 
the observed increase of the slope would correspond to the 
interaction of ~ cyclodextrin with the ionized species. 
Without such interaction, the pH 2 line should have been 
parallel to those obtained at the other pH values. However, 
in the case of ibuprofen and hydrochlorothiazide, the SAS 
treatment showed that there was no significant difference in 
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( the slope as a function of pH i.e. for these two drugs the 
ionized species does not interact significantly with ~ 
cyclodextrin. 
In order to rationalize the differences in complexation 
behavior, one has to consider the basic mechanism of 
inclusion complex formation. The cavity of cyclodextrin is 
an hydrophobic environment that can host an hydrophobic 
molecule. It seems that ~ cyclodextrin can fit a group 
similar to the benzene ring, which is one of the groups 
present in diazepam and phenytoin that has previously been 
shown to form a complex at the ionized state. For these two 
molecules the complexing group may remain mostly unaffected 
by the ionization and therefore the ionized species is still 
able to form a complex with cyclodextrin. Ibuprofen and 
hydrochlorothiazide do not form such a complex after 
ionization and the slope of the solubility isotherms is pH 
independent. It is possible that the ionization of both 
drugs greatly affects the polarity or the hydrophobicity of 
the complexing group, thus preventing the formation of a 
complex at higher pH values. 
Effect of temperature on complexation- The solubility 
study was also conducted at different temperatures for each 
of the three drugs studied. Figure 7 shows an example of 
the plots obtained at each pH value. The analysis of 
variance using SAS did not show any significant difference 
of the slopes tested, which means that the solubilization 
power was essentially temperature-independent. 
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Three-dimensional plots obtained at given pH values using 
SASGRAPH are shown in Figures 8, 9 and 10 for ibuprofen, 
hydrochlorothiazide and diazepam, respectively. 
Determination of thermodynamic parameters- The 
classical method to determine thermodynamic parameters of 
complexation is based on the temperature dependence of the 
complexation constant. However, this method based on two 
sequential steps of linearization of data, does not allow a 
precise determination of the enthalpy and entropy of 
complexation, which can make difficult further comparisons. 
The computer method developed in this study utilized 
datafiles that contained a set of solubility data at one pH 
value similar to that plotted in Figures 8 to 10. 
Tables II, III and IV summarize the results of the 
treatment of the solubility data for the three drugs. The 
thermodynamic parameters of complexation can be used as a 
basis for discussion of the mechanism of complexation. The 
driving forces of complexation have long been a subject of 
controversy (13,14). The different possibilities proposed 
include hydrophobic interaction, hydrogen bonding, Van der 
Waals interaction, release of enthalpy rich water molecules 
and release of conformational strain (15) . The contribution 
of each of these factors depends upon the nature of the 
drug. The overall thermodynamic parameters, namely enthalpy 
(6H) and entropy (AS) are releated to the apparent free 
energy (6G) by the Gibbs equation: 
AG = .CiH - T 65 ( 4) 
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The free energy can be considered as the sum of the energy 
changes due to each of the factors listed earlier. 
Therefore, the values given in Tables III to IV can be seen 
as overall thermodynamic parameters, that indicate which 
factors may be predominant in the mechanism of complexation. 
In the case of ibuprofen, the apparent enthaply of 
complexation is negative at all pH values indicating that 
the system is releasing energy upon complexation . The 
extent of the energy released decreases as the drug becomes 
more ionized. There is no definite trend in the change in 
enthalpy from pH 2 to pH 5. However, the large negative 
enthalpies probably indicate a strong involvement of dipoles 
and Wan der Waals interaction during complexation. Also 
this loss of heat upon complexation could correspond to the 
energy released by the enthalpy rich water molecules trapped 
within the cyclodextrin cavity. The entropy factor is 
positive at all pH values, showing that the order of the 
systems decreases upon complexation. At pH 6, the entropy 
increase is particularly significant despite the high 
standard deviation . Ibuprofen is quite ionized at pH 6 and 
it is likely that some water molecules of salvation are 
still in contact with the drug molecule. If one considers 
that the change in entropy corresponds to the difference in 
hydrogen bonds before and after complexation, one could 
suggest that the larger overall balance is due to the 
smaller number of hydrogen bonds broken. 
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The thermodynamic parameters of complexation for the 
diazepam/ ~ cyclodextrin interaction are presented in Table 
III. The enthalpy of complexation is again negative at all 
pH values. As pH decreases and drug ionization increases, 
the absolute value of H decreases. This lower value of H 
indicates a weaker binding and a lower loss of heat upon 
complexation. It has also been proposed that the 
complexation of an ionized species would occur on a more 
random fashion than for the ionized species (16). The 
entropy value is positive and increases as the pH is 
increased. As for ibuprofen, the entropy can be correlated 
to the forming and breaking of hydrogen bonds upon 
complexation. The ionized form of diazepam probably keeps a 
water salvation in the surroundings and gains hydrogen 
bonding without loosing such a great amount as in pH 6. The 
overall result is a larger entropy upon complexation. Also, 
as the pH decreases the water molecules are more tightly 
bound to the drug molecule and therefore are only slowly 
removed, partially explaining the high entropy values. 
The results shown in Figure IV for the complexation of 
hydrochlorothiazide with ~ cyclodextrin are less dramatic 
but possibly easier to interpret. 
weak acid with a pKa around 8.0. 
Hydrochlorothiazide is a 
It seems that the 
ionization of the drug has very little effect on the 
thermodynamic parameters of complexation. This result also 
confirms the fact that hydrochlorothiazide does not form a 
complex with ~ cyclodextrin in its ionized form. The 
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negative values of enthalpy testifies again of the stong 
involvement of the enthalpy rich water during complexation. 
The large negative values of entropy suggest that the system 
becomes more ordered upon complexation. 
SUMMARY 
From the results for the complexation of three drugs 
with cyclodextrins, it appears that the main driving forces 
of complexation reside in the release of energy of the water 
molecules entrapped in the cyclodextrin cality. Althouh the 
negative enthalpy value was a common point between the drugs 
tested, the extent of the pH effect varied from one molecule 
to another. The entropy is probably more related to the 
solvent participation in the complexation phenomenon. The 
consideration of the interaction between water and non-polar 
drug, water and cyclodextrin before complexation as well as 
the breakage and establishment of hydrogen bonds, allowed 
for a description of the complexation mechanism for each 
drug. However, this drug / cyclodextrin interaction depended 
on the nature of the drug and the pH of the solution. The 
practical biopharmaceutical implications of the results can 
be quite significant . A drug / cyclodextrin complex dosage 
form either for parenteral or oral administration, would 
encounter various pH conditions in-vivo. The therapeutic 
effect might well be affected by the mechanism of 
complexation. Further work is still needed to fully explain 
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negative values of enthalpy testifies again of the strong 
involvement of the enthalpy rich water during complexation. 
The large negative values of entropy suggest that the system 
becomes more ordered upon complexation. 
SUMMARY 
From the results for the complexation of three drugs 
with cyclodextrins, it appears that the main driving forces 
of complexation reside in the release of energy of the water 
molecules entrapped in the cyclodextrin cality. Althouh the 
negative enthalpy value was a collUllon point between the drugs 
tested, the extent of the pH effect varied from one molecule 
to another. The entropy is probably more related to the 
solvent participation in the complexation phenomenon. The 
consideration of the interaction between water and non- polar 
drug, water and cyclodextrin before complexation as well as 
the breakage and establishment of hydrogen bonds, allowed 
for a description of the complexation mechanism for each 
drug. However, this drug/cyclodextrin interaction depended 
on the nature of the drug and the pH of the solution. The 
practical biopharmaceutical implications of the results can 
be quite significant. A drug / cyclodextrin complex dosage 
form either for parenteral or oral administration, would 
encounter various pH conditions in-vivo. The therapeutic 
effect might well be affected by the mechanism of 
complexation. Further work is still needed to fully explain 
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the exact mechanism of drug / cyclodextrin complex formation 
and to eventually optimize complex formulation. 
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TABLE I: Heat of solution of the drugs at various pH values 
DRUG pH 
2 
4 
IBUPROFEN 5 
6 
2 
DIAZEPAM 3 
4 
6 
5 
HYDROCHLORO- 8 
THI AZ IDE 9 
AH
5 
(linear) 
-1 (cal.mol ) 
11,158.8 
10,534.1 
6,287.5 
4,685.9 
311. 2 
1,565.2 
3,724 .9 
5,381.4 
10,392.2 
9,756.2 
8,808.9 
~H5 (non-linear) 
(cal.mol -l) 
8,718.9 ± 1,266.2 
9,447.9 ± 1,223.0 
6,207.5 ± 375.7 
4,157.7 ± 385.8 
1,246.8 ± 543.2 
1,459.9 ± 289.6 
5,368.5 ± 716.0 
6,509.3 ± 565.4 
9,420.3 ± 327.4 
10,313.4 ± 332.2 
9,157.6 ± 330.3 
126 
TABLE II: Ibuprofen/ ~ cyclodextrin complexation 
pH 
2 
4 
5 
6 
thermodynamic parameters 
r 
0.999 
0.999 
0.999 
0.991 
tlH std. dev. 
-1 (cal.mol ) 
-6,925.5 324.9 
-7,797.9 321.7 
-7,045.5 300.0 
-4,036.4 1,246.6 
~s std. dev. 
(e.u.) 
+3.49 1.06 
+0.88 1.05 
+O. 72 0.97 
+8.15 4.06 
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TABLE III: Diazepam/ ~ cyclodextrin complexation 
pH 
2 
3 
4 
6 
thermodynamic parameters 
r 
0 .960 
0.998 
0.998 
0 .999 
std. dev. 
-1 (cal.mol ) 
-51. 4 
-797 .9 
-4 ,070 .7 
-4,416.4 
1502.4 
145 .7 
184.2 
104.3 
[)S std. dev. 
(e.u.) 
+16.63 4.89 
+16.50 0 . 47 
+ 5.22 0.60 
+ 4.44 0.34 
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TABLE IV: Hydrochlorothiazide / ~ cyclodextrin complexation 
pH 
5 
8 
9 
thermodynamic parameters 
r 
0.997 
0.997 
0.996 
std. dev. 
-1 (cal.mol ) 
-9,642.3 
-9,322.1 
-10,012.2 
432.3 
574.1 
715. 9 
+ 14.7 
+ 14.1 
+ 16.7 
std. dev. 
(e.u.) 
1. 4 
1. 9 
2 . 3 
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Figure 1 
Van't Hoff plots for ibuprofen 
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Figure 2 
Van't Hoff plots for diazepam 
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Figure 3 
Van't Hoff plots for hydrochlorothiazide 
( 
N 
I-
u 
I 
et:: 
C) 
LL 
Ul 
I-
C) 
_J 
0.... 
LL 
LL 
C) 
I 
I-
-z 
< 
> 
C) 
(T) 
I 
lJl 
(T) 
I 
C) 
.q-
i 
lJl 
.q-
i 
<AlilIBnlOS NOilJV~~ 310H) ~01 
lJl 
(T) 
(T) 
(T) 
(T) 
N 
(T) 
(T) 
C) 
c:fTJ 
lJl 
I 
135 
,...... 
; 
::.::: 
...... 
"' C) 
x 
I-
'-
Figure 4 
Effect of pH on the solubilit~ isotherms of 
ibuprofen at 50 c 
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Figure 5 
Effect of pH on the solubilbty isotherms of 
diazepam at ~O c 
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Figure 6 
Effect of pH on the solubility isgtherms of 
hydrochlorothiazide at 40 c 
140 
141 
I/) 
-. O'I CD 11'1 
a. a. a. 
<I 
• a (J 
0 
0 
...,. 0 
(\J 
-. 
,_ 
~ 
a 
~ 
~ ::i: ,_ 
0 
-. 
...... 
:k 
0) >< N ,_ 
0 (J ::i: 
~ (J k 0 
~ 
...... 
~ CD [J 
~ 
...... 
8 
,_ 
-' 
~ 
(J 
[J 
>-(J 
-J 
~ 
0 (J 
C'l') 
( 
Figure 7 
Effect of temperature on the solubility isotherms of 
diazepam at pH 4 
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Figure 8 
3D plot of the solubility of ibuprofen at pH 5 
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Figure 9 
3D plot of the solubility of HCTZ at pH 8 
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Figure 10 
3D plot of the solubility of diazepam at pH 6 
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INTRODUCTION 
The dissolution of poorly soluble drugs can be the 
major limitation in the design of suitable solid dosage 
forms (1). The absorption rate is usually much higher than 
the dissolution rate in the gastro-intestinal tract. 
Therefore an increase in the dissolution properties for many 
drugs is likely to lead to higher bioavailability (2). Much 
research has already been done in the field of pharmaceutics 
to improve the dissolution of poorly absorbed drugs (3,4). 
Different techniques have been proposed such as 
micronization (5,6), grinding (7) and preparation of solid 
dispersions (8,9,10). The term solid dispersion refers to 
the dispersion of an active drug in an inert carrier or 
matrix (11), such as polyethylene glycol (PEG), urea, 
mannitol or polyvinylpyrrolidone (PVP). The complexation of 
drugs with beta cyclodextrin is a particular case of solid 
dispersion, in which the drug is actually encapsulated on a 
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molecular basis in an hydrophilic oligosaccharide composed 
of seven units of glucose (12) . 
cyclodextrins have been shown to have the ability to 
form inclusion complexes with drugs, which exist both in 
solution and in the solid state. This is the basis of the 
preparation of a solid dosage form containing a 
drug / cyclodextrin complex as the active ingredient. The dry 
method consists of a mechanical mixing of the drug with 
cyclodextrins. Different ratios of the two components and 
various methods of mixing can be used (13). Such 
formulations have been successfully prepared using grinding 
and roll-mixing . The advantages of the dry method include 
simplicity, one-step process and exact knowledge of the 
blend content. The second or wet method consists of a 
two-step process. The first step is the formation of the 
drug / cyclodextrin complex in solution. Drug and 
cyclodextrin are solubilized in a solvent according to a 
definite ratio and the solution is shaken until equilibrium 
is reached (14). The second step is the removal of the 
solvent. Different techniques have been proposed to prepare 
the dry complex, such as solvent evaporation (15), kneading, 
spray-drying (12) and freeze-drying (16). Upon drying, the 
complex obtained is usually amorphous (17), with two 
specific properties: a smaller particle size and a reduced 
crystal growth, due to the fast removal of water molecules 
(18). It has been well reported that amorphous forms have 
the largest energy and exhibit faster dissolution. Rarely 
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in the literature are the dissolution profiles of 
drug / cyclodextrin complexes compared with those of the pure 
drug subjected to the same process (19). It is therefore 
often difficult to interpret the data, that compare 
dissolution rate of an amorphous form with a crystalline 
form. 
Two main criteria should be taken into consideration in 
the development of a solid dosage form of drug / cyclodextrin 
complex: the stoichiometry of the complex and the degree of 
complexation, that can be evaluated from the slope of the 
phase-solubility diagram. The stoichiometry of the complex 
can be determined using different techniques such as Job's 
plots, titrations or physical analysis by X-Ray 
crystallography, Infra-Red and Differential Scanning 
Calorimetry. T. Higuchi also determined the stoichiometry 
of complexes from the plateau region observed in the 
phase-diagram solubility of certain insoluble complexes 
(20). The slope of the solubility isotherms is also an 
useful indicator of the extent of complexation. It 
represents a ratio of the respective amounts of drug and 
cyclodextrin actually entering the complex. A slope higher 
than one suggests the formation of a l:x complex (x>l). A 
slope lower than the unity can correspond either to a 1:1 
complex with low affinity between drug and cyclodextrin or 
to the formation of a y:l (y<l). For such a complex, the 
solution ready for drying does not contain exclusively the 
drug:cyclodextrin inclusion compound. There is also in 
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solution a substantial amount of free drug and free 
cyclodextrin. An intermediate step of filtration or 
purification should then be used to ensure the complete 
isolation of the complex. Finally, the advantage of the 
precipitation method is the higher purity of the product 
obtained. 
The drug considered in this study is phenytoin, a 
widely used anticonvulsant. Phenytoin has a low aqueous 
solubility and follows non-linear pharmacokinetics (21 , 22). 
The complexation of phenytoin with cyclodextrin is expected 
to result in higher bioavailability and decrease in the 
intra- and inter-variability of the absorption in patients. 
The objectives of the study are to investigate the 
potential use of beta cyclodextrin as dissolution enhancer 
in mechanical mixtures of phenytoin and cyclodextrin. Also, 
the study focusses on the dissolution profiles of direct 
compression tablets, prepared using various 
drug / cyclodextrin ratios and different methods of mixing . 
EXPERIMENTAL 
Materials 
Phenytoin was obtained from Sigma Chemicals and used as 
received. The cyclodextrin materials were a generous gift 
of American Maize. Avicel PH101, Primojel, magnesium 
stearate and sodium bicarbonate were all of USP grade 
suitable for use in pharmaceutical research. 
l~ 
Methods 
Formulations 
Several formulations were prepared. Tables 1 and 2 
show the amount of each ingredient (% w/ w) in the differents 
blends. The percentage of cyclodextrin in Table 1 
corresponds to 1:0, 1:1 and 1:2 as drug:cyclodextrin ratio 
(% w/ w). In Table 2, a 1:1 ratio was used for all the 
formulations, which contain various percentages of sodium 
bicarbonate. This 1:1 stoichiometric ratio has been shown 
to be that of the complex formed in solution. Blends of 25 
grams were prepared using a Turbula Rapid Blender, in three 
steps: 
1. Mix phenytoin and cyclodextrin for ten minutes. 
2. Add Avicel pH 101 and mix for ten minutes. 
3. Add magnesium stearate and mix for five minutes. 
The formulation variables considered were the order of 
mixing and the method of mixing, as described in Table 3. 
The blends were then compacted on a model F single-punch 
Stokes tablet press. The target specifications of the 
tablets manufactured are listed in Table 4. 
Evaluation of tablets 
All the tablets were tested according to USP standards. 
The tablets from all batches did meet the desired 
specifications . Dissolution studies were conducted using 
the USP paddle method, in pH 7.4 phosphate buffer and 
distilled water. Samples were taken manually at 15, 30 and 
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60 minutes in triplicate. The medium was replaced after 
each sample withdrawal and final concentrations were 
computed by taking into account medium replacement. 
Phenytoin concentrations were determined using a 
Hewlett-Plackard diode-array ultra-violet spectrophotometer. 
The standard calibration curve obtained at 222 nm obeyed the 
Beer's law. 
RESULTS AND DISCUSSION 
Different models have been developed to describe the 
dissolution of drugs. The following equation shows the 
relationship between dissolution rate and some critical 
parameters using the simplest theory: 
dM/ dt = K S (CS - C) 
where dM/dt is the dissolution rate 
K is the ratio of diffusion coefficient 
and thickness of the stationary layer 
S is the effective surface area 
( 1) 
CS is the saturation solubility of the drug 
and C is the drug concentration at time t 
This equation shows that both particle size and 
saturation solubility directly affect the dissolution rate. 
For instance, the effect of micronization of the drug on 
dissolution rate can be readily explained from this 
empirical equation. 
Figure 1 shows the dissolution profiles of phenytoin 
from tablets containing different amounts of cyclodextrin. 
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As the ratio of drug:cyclodextrin increases, the dissolution 
rates increases, suggesting that cyclodextrin promotes the 
transport of the drug from the dosage form into the 
dissolution medium. Cyclodextrin may behave either as an 
extra-granular disintegrating agent or as an in-situ 
solubilization agent. The larger the amount of 
cyclodextrin, the higher the probability for the drug 
molecules to interact with cyclodextrin. It can be 
mentioned that the increase in dissolution rate, although it 
was statistically significant, was not dramatic. 
Figure 2 shows the effect of grinding on the 
dissolution rates of phenytoin. Grinding resulted in a 
significant increase in dissolution, which can be explained 
by two different factors. Grinding is a process mainly used 
to decrease particle size of certain drugs. It has been 
shown that ground phenytoin formulations exhibited higher 
dissolution characteristics and better bioavailability 
(7,23). It is thus likely that the increase observed in 
Figure 2 corresponds to an increase of the specific surf ace 
area. Due to the intimate character of grinding, it is also 
possible that the tortuosity of the system is changed, with 
a change in the diffusion properties of the drug molecules 
from the tablet into the bulk (18). This effect would also 
explain the results shown in Figure 3, where the dissolution 
rate of the tablets made using method 2 is significantly 
lower than that observed using the first method. The lack 
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of interaction between the drug and cyclodextrin during 
mixing may be related to the negative effect on dissolution. 
Sodium bicarbonate has the property to change the 
microenvironment around the dissolution particles and to 
promote dissolution of acidic drugs. The dissolution 
profiles of the tablets made using various amounts of sodium 
bicarbonate are shown in Figure 4 and 5. The two 
dissolution media used were pH 7.4 phosphate buffer and 
distilled water. A significant increase was observed in 
Figure 4, that shows that sodium bicarbonate affects the pH 
of the dissolution medium, thus resulting in higher 
concentrations. However, the increase does not appear to be 
very extensive. Figure 5 confirms that sodium bicarbonate 
does not have a dramatic effect on the dissolution rates of 
phenytoin. The data overlapped after 45 minutes, showing no 
trend or difference from one formulation to another. 
SUMMARY 
From the results of this study, it appears that beta 
cyclodextrin does enhance the dissolution of phenytoin. 
However, the relatively small extent of the increase in 
dissolution rate is unlikely to justify the use of this 
approach simply to increase dissolution rate, although, of 
course, cyclodextrin has a clearly identified role in 
increasing equilibrium solubility. Grinding actually seemed 
to have been the main factor, and can be compared to 
freeze-drying as an additional formulation process, that can 
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interfere with the basic effect of cyclodextrin complexation 
in drug dissolution. A physical analysis would allow a 
better establishment of the crystal nature on a qualitative 
basis. 
In conclusion, the use of beta cyclodextrin as a 
non-complexed additive in direct compression formulation 
seems for phenytoin to be of limited value. A more positive 
effect might well be observed using wet ' granulation, in 
which water or other solvents would allow the formation of 
the inclusion complex. Cyclodextrin could then play the 
role of intra-granular disintegrating agent and is likely to 
promote a larger increase in dissolution rate. Also 
preformulation data such as solubility studies, degree of 
interaction and stoichiometry determination should be the 
basis of the development of drug:cyclodextrin complexation. 
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Table 1: Phenytoin:~ cyclodextrin formulations ( % w/ w) 
drug:~ CD ratio 
1:0 1:1 1:2 
Phenytoin 8 8 8 
~ cyclodextrin 0 36 72 
Avicel pH 101 89 53 17 
Primojel 2 2 2 
Magnesium stearate 1 1 1 
Table 2: Phenytoin:~ cyclodextrin formulations 
containing sodium bicarbonate (% w/ w) 
Batch # 
Nal2 Na24 Na36 
Phenytoin 8 8 8 
~ cyclodextrin 36 36 36 
Avicel pH 101 41 29 17 
Primojel 2 2 2 
Magnesium stearate 1 1 1 
Sodium bicarbonate 12 24 36 
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Table 3: Process variables 
Mixing process Order of mixing Method 
regular mixing (phenytoin + cyclodextrin) + Avicel 1 
(phenytoin + Avicel) + Cyclodextrin 2 
grinding (phenytoin + cyclodextrinl + Avicel 1 
164 
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Table 4: Tablet specifications 
Parameter Unit Specification 
Weight (mg) 325 ± 15 
Hardness (Kg) 4 - 7 
Friability (%) LT 0.8 
Disintegration time(s) LT 180 
Diameter (inch) 0.378 ± 0.001 
Thickness (inch) 0.205 0.005 
Figure 1 
Dissolution profiles of phenytoin at 37°c in water 
Effect of drug:CD ratio 
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Figure 2 
Dissolution profiles of phenytoin at 37° in water 
Effect of mixing process 
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Figure 3 
Dissolution profiles of phenytoin at 37°c in water 
Effect of order of mixing 
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Figure 4 
Dissolution profiles of phenytoin at 37°c 
Effect of dissolution medium 
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Figure 5 
Dissolution profiles of phenytoin at 37°c and pH 7.4 
Effect of sodium bicarbonate 
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the drugs studied, thus preventing any interaction of the 
ionized species with cyclodextrin. 
A novel computerized method of determination of 
thermodynamic parameters of the complexing group was 
developed and validated. The method allowed for a precise 
determination of enthalpy and entropy of complexation with 
known standard deviation. A large negative enthalpy was 
observed for all four drugs, suggesting a rather enthalpy 
controlled mechanism. This result shows the involvement of 
the enthalpy-rich water molecules trapped in the 
cyclodextrin cavity during complexation. Strong dipole 
interactions as well as Van der Waals forces are likely to 
accompany the complexation process. Classical hydrophobic 
interaction does not seem to play a major role. The results 
for the entropy of complexation indicate both the importance 
of the solvent and the differences in complexation behavior 
of the different drugs. Water seems to play a major role in 
the complexation phenomenon due to its ability to form 
hydrogen bonding. According to the nature and the polarity 
of the guest molecule, the extent of hydrogen bonding might 
vary and thus affect the stability of the complex. 
The new chemically modified beta cyclodextrin was shown 
to have a great potential for the pharmaceutical industry. 
The solubilization power observed from the solubility data 
was basically identical to that obtained with the natural 
beta cyclodextrin. The total concentration reached in the 
case of phenytoin and ibuprofen could very well lead to new 
CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
CONCLUSIONS 
The solubility method has been shown to be an excellent 
practical mean of studying the complexation of drugs with 
cyclodextrins. From the solubility data obtained, a linear 
relationship was observed between the drug and the 
cyclodextrin concentrations. The general theory of "hand 
and glove" or "lock and key" applied for the four drugs 
studied. Beta cyclodextrin was shown to have the best 
complexing ability, suggesting that the steric factors are 
likely to control the complexation phenomenon. This result 
was also confirmed from the comparative study of the natural 
and the chemically modified beta cyclodextrin. A change in 
the external structure of the host molecule did not affect 
the solubilization power. However, the steric factors are 
not sufficient to explain the differences from one drug to 
another or from one degree of ionization to another. For 
two drugs, ibuprofen and hydrochlorothiazide, the ionized 
species have been shown not to interact with beta 
cyclodextrin, whereas the ionized form of phenytoin and 
diazepam had the ability to form a complex. These 
differences in behavior might well be due to the structure 
of the drugs. The ionization seemed to have an effect on 
the hydrophobic character of the complexing group of two of 
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dosage forms, with improv ed bioavailability or better 
organo-leptic properties. 
The formulation of phenytoin with cyclodextrin using a 
dry method without the intervention of solvents, did not 
show a great improvement in dissolution profiles. This part 
of the study pointed out the importance of water or other 
solve~ts to ensure an efficient interaction between drug and 
cyclodextrin . 
SUGGESTIONS FOR FUTURE WORK 
The physico - chemical a s pects of complexation still 
deserve and necessitate a great amount of research before a 
clear elucidation of the complexation process can call for a 
full development of this new formulation tool . The main 
areas that can be mentioned are: 
1. To investigate the thermodynamics of a series of drug 
analogs, and to compare the parameters of complexation. The 
computer method developed in this thesis could be valuable 
in the comparison process . A specific of the effect of 
particular substituents upon complexation could be 
identified. 
2. To carry a full study in hydro-alcoholic mixtures. The 
change of polarity of the solvent would affect the stability 
of the complex and the thermody namics of the mechanism. An 
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optimization of the solvent polarity could lead to an 
improved solubilization of drugs . 
3. To evaluate the potential of complexation applications of 
different cyclodextrin derivatives. Two classes of new 
compounds could be evaluated. Hydrophilic derivatives with 
v arious structures, substituents and degree of substitution 
could be used to increase optimally the solubility of poorly 
water-soluble drugs. Also a new class of hydrophobic 
derivatives could be investigated for their potential use as 
carriers in sustained release of soluble drugs. 
4. To investigate the use of cyclodextrin on the dissolution 
of tablets prepared by wet granulation. A possible 
correlation between preformulation data formulation 
performance could be then established. 
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APPENDIX A 
RELATIONSHIP BETWEEN COMPRESSION PROFILE 
AND PHY SI CAL PROPERTIES OF A 
LITH I UM CARBONATE FORMULATION 
M.G . DEDHIYA AND C.W . WOODRUFF 
HILES PHARMACEUTICALS 
DIVISION OF MILES LABORATORIES . INC. 
WEST HAVEN, CT 065 16, USA 
AND 
C.T. RHODESX AND F.A. MENARD 
COLLEGE OF PHARMACY, UNIVERSITY OF RHODE ISLAND 
KINGSTON , RI 02881, USA 
ABSTRACT 
Relationship between the comp re ssion profile and 
physical properties of a directly compressed lithium 
carbonate tablet formulation was examined using an 
instrumented tablet press . The measured physical 
parameters included hardness, disintegration time, 
and dissolution. A linear correla t ion was observed 
X To whom all inquiries should be directed. 
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between the compressi o n f o r c e, 4 0 0 0 t o 7020 l bs . and 
tablet hardness, 5 to 9 Kp . The disinte g ration time, 
80 to 100 seconds. did not significantly change with 
the increasin g compression fo r ce. Dissolution of 
lithium carbonate tablets complie d with the USP 
limits at all compression forces . A dissolution rate 
maximum related to compression force was observed . 
The ove r all results indicate that the processing 
parame t er, compression force, affects the physical 
properties o f the tablet formulation. 
INTRODU CTION 
The compres sio n force is one of the critical 
physical factors which affects the dissolution and 
disi n teg r ation time and hardness of tablet dosage 
form ( 1-8 ) . Seve ral investigators (9) have examined 
methods to study relationship between the applied 
compression for c e and tablet prope r ties . The purpose 
of this inv est ig ati o n was t o cha racterize a 
relationship between the compressio n force and 
physical propert i es o f a directly c o mpressed lithium 
ca rbonate formu l ~ tio n. Once t he correlatio n is 
established, the com pre s sion force measu rement can be 
used to monit o r tl1 e phys i cal pr o pert i es such as 
hardness and dissol ut io n o f the active drug . 
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MATERIALS 
A directly comp re ssed lithiu m carbonate 
formulation included the follo wing ingredients: 
lithium carbonate USP, co r n sta rch US P, calcium 
phosphate dibasic USP , polyethylene glycol USP, 
magnesium stearate USP , a nd s o dium lauryl sulfate 
USP. 
METHODS 
Two kilograms of direct compressible blend was 
prepared by mixing 60% of the formula lithium 
carbonate, corn starch, calci um phosphate, dibasic; 
and polyeth y lene glycol i n a laboratory V-blender for 
20 minutes. A sufficient quantity of lubricant mix 
containing the remainin g materials was added and the 
mixing was continued for an addit ional 10 minutes. 
The particle size of the blend was de termined usin g a 
sieve analysis, bul~ and t apped densities were 
measured usi ng a JEL appa r a tusl. The blend was 
compressed us i ng a r ota ry tablet press with a 
standard r oun d tooling of 3/8 inch diameter and the 
compression for ce was measured using strain 
J . Engelsmann, AB . , Ludwigshafen, West Germany. 
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guages2 and a high speed analog rec o rder3. The 
physical properties of tablets were determined as 
follows: tablet hardness was measured with a 
Schleuniger4 hardness tester and disintegrations 
and dissolution6 tests were performed according t o 
the USP procedures. Lithium carbonate analysis was 
performed using an atomic absorption7 
spectrophotometric analysis and products complied 
with all USP requirements. 
RESULTS AND DISCUSSION 
Table l shows the physical properti es of the 
major ingredients of the formulation. The percentage 
compressibility was computed as follows: 
% compressibility = (Dt - Db) / Dt 
where Dt and Db are tapped and bulk densities, 
respectively. 
2 Manesty B3B t abl et press, Manesty Machine Ltd . , 
Liverpool, Englan d . 
3 Gould 2200 Recorder, Gould Inc ., Cle veland, OH 
USA. 
4 Schleuniger Hardness Tester, Vector Corp., 
Marion, IA USA . 
5 Tablet Disintegration Tester, Van Kel Industries, 
Chatham, NJ USA . 
6 Dissolut ion Appa rat us , Hanson Research 
Corporation, North idg e , CA USA 
7 Instrumentati o n Laboratory AA Spect roph o t om eter, 
Instrumentati on Labo ratory, Inc. ,Lexington, MA USA . 
185 
f 
Lithium carbonate, which showed poor flow 
properties represented 60% w/ w of the formulation. 
The three ingredients listed in Table l accounted for 
more than 95% w/ w of the gran ul a tion . The particle 
size distribution of the different ingredients used 
in this formulation is shown in Figure 1. Lithium 
carbonate exists as a very fine powder with 90% w/ w 
less than 44 microns. The plot also shows that the 
final blend exhibited a poor particle size 
distribution with 90% w/ w of the blend containing 
particles less than 74 microns. 
A typical compression profile of the lithium 
carbonate formulation is shown in Figure 2. The 
highest peak represents the maximum compression force 
developed during tableting. In this study, the 
maximum compression force varied from 4000 to 7020 
lbs. Below 4000 lbs compression force, the tablet 
friability excee d~d a 1% limit and above 7020 lbs, 
tablet capping was obse rved. 
Relationsh ip between compression force and 
hardness of lithium carbonate tablets is represented 
in Figure 3. The results show that the compression 
force exhibit s a li near rel ations hip with hardness 
(r2 >0 . 99), leading to an acceptable product in 
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terms of compressibility. The compression force and 
hardness ranges are adequate for incorporating these 
values in scale up manufacturing of the product. 
Disintegration time was measured using the USP 
procedure. All tablets disintegrated within a time 
range from 80 to 100 seconds. No significant 
differences were obse r ved in the disintegration time 
from one compression force to another. 
Dissolution of lithium carbonate tablets was 
examined using the USP XXI basket procedure . The 
dissolution profiles at different compression forces 
are shown in Figure 4. This formulation exhibits the 
dissolution compression force relationship in which 
the initial dissolution at 15 minutes is faster to a 
maximum as the compression force is increased and 
then further increases in the compression force slow 
the initial dissolution of lithium carbonate. These 
results correlate extremely well with those obtained 
by Smith et. al ( 6) on dissolution of tablets 
prepared by a wet granulation of lithium carbonate. 
These investigators studied the dissolution at 20 
minutes and tablet hardness relationship of a lithium 
carbonate formulati o n c ontai ni ng lithium carbonate, 
lactose, cornstarch and magnesium stearate. In their 
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study, the tablet hardness was increased using higher 
compression force. The dissolution at 20 minutes 
showed two maxima as the ha rdness of the tablets were 
increased. 
Levy et. al (5) showed that the initial 
dissolution rates of salicylic acid tablets increased 
when the tableting c ompression force was increased. 
This increase in dissol uti on of salicylic acid was 
attributed to fracturing of the drug particles at 
hi ghe r force yielding smaller particles with 
increased surface area. In case of the directly 
compressed lithium carbonate, initia l increase in the 
compress f o r ce pr o bably results to fr acture of 
lithium carbonate and subsequent increase in the 
compression force leads to bonding and or the 
fusion. The fr act ure and bonding mechanism is 
postulated t o inc r eas e and decrease the apparent 
surface area of lithium ca r bonate . This increase or 
decrease, ther efo re, enhances o r retards the initial 
dissolution flux of l ithium carbonate. The 
thermodynamic s olubi lity governing mechanism, 
independent of the su rfa ce area, controls the amount 
of drug diss olved afte r 45 minu tes a s indicated by a 
constant plat eau v~lue . Tt is pos sible that such 
fracture and bonding of lithium ca r bo nate can yield a 
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dissolution rate maximum. 
CONCLUSION 
Results of this study show that the compression 
force is directly correlated to the hardness of 
lithium carbonate tablets. The results of initial 
dissolution rate show a ~, ximum when the compression 
force is increased . It is suggested that the 
dissolution behavior is caused by the fracture and 
bonding of lithium carbonate. The method described 
in correlating the compression force with physical 
properties provides a process monit o ring procedure 
for lithium carbonate tablets. 
REFERENCES 
1. Greist, J.H., Jefferson, J.W., and 
Marcetich, J., Behavioral Medicine, 12, 25 
( 1978 ). 
2. Wall, B.P., Parkin, J . E., and Sunderland, 
V. B., Australian Journal of Pharmaceutical 
Sciences, 7, 57 ( 1978). 
3. Wall, B.P ., Parkin, J . E., Sunderland, V.B., 
and Zorbas , A., J. Pharm. Pharmacol, 34, 601 
(1982 ) . 
4. Ritschel, W. A. and Parab , P ., Drug 
Development and Industrial Pha rmacy, 11, 147 
(1985 ) . 
189 
5. Levy, G. , Antkowiak, J.M., Procknal, J.A., 
and White, D.C . , J. Pharm . Sci , 52 , 10 47 
( 1963). 
6. Smith, H. , Bake r, C., and Hood , J .W., J . 
Pham. Pha rm acol , 23 , 536 (1971) . 
7. Higuch i , T., Elowe , L.N . , and Busse, L . W., 
J. American Pharm . Association, 43, 685 
( 1954 ) . 
8. Nystrom, C., Mazur, J . and Sjogren, J. 
Int. J . Pharmaceutics, 10, 209 (1982) . 
9 . Parrott, E . "Compression" in Pharmaceutical 
Dosage form, Table ts vo lume II, Edited By 
Liberman, H. and Lachman, L ., Marcel Dekker, 
Inc., New York, 1980. 
190 
TABLE 
Physical Properties of Ingredients 
Ingredients Bulk Density Tapped Density % Compressibilty 
(g I cc) (g I cc) 
J...jthium Ca r\J onat.e 0.53 0.80 34 
Di c alcium Pho s phat e 0.92 1. 4 7 37 
Corn S tarch 0.59 0. 78 24 
Formulation Bl e nd 0.63 0.90 30 
-~ 
Figure 1 
Particle size distribution of the 
lithium carbonate blend 
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Figure 2 
Compression profile 
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Hardness / compression profile 
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Figure 4 
Dissolution profiles of lithium carbonate 
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APPENDIX B 
( 
A Comparative Study of Several Lactose 
Products for Direct Compression Tabletting 
F.A. Menard and C.T. Rhodes 
University of Rhode Island. RI 
J . Kanig 
Kanig Consulting and Research Associates . CT 
ABSTRACT 
Physical characteristics such as density , flow and compaction 
properties of four brands of anhydrous lactose were evaluated . 
The drug capacity of the four products was studied by preparing 
10% and 20% hydrochlorothiazide tablets. Plots of the tablet 
hardness as a function of the compaction force are presented. It 
was possible to make tablets with acceptable properties with all 
four products. A lubrication study was conducted by varying the 
amount of l ubricant from 0 . 27. to 0.47.. The ejection force was 
plotted as a function of the compaction force. The lubrication 
profiles showed that an increase from 0.27. to 0.3% of l ubricant 
led to a s i gnificant decrease of the ejection force. All tablets 
were evaluated for hardness, thickness , friability and 
disintegration. Furthermore, the reworkability was shown to be 
technically feasible with all products. 
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INTRODUCTION 
It is widely recognized that different brands of a same 
ingredient used in a tablet formulation can lead to a significant 
change in the physico-chemical properties and the stability of 
tablets as well as the in vivo performance of the drug (6,7). The 
objective of the study was to compare four commercially available 
anhydrous lactose products. Three of the products considered had 
the same structure, whereas the fourth product, despite a 
different structure, could very well be used for similar 
formulation purposes. The study was limited to one drug and two 
lots of each product. 
MATERIAL AND METHODS 
MATERIALS 
The anhydrous lactose products were obtained from Sheffield 
Products1, Foremost2 , Dairy Crest3 and De Melkindustrie Veghel4 . 
Two lots of each product were used. The drug used in the 
formulations was hydrochlorothiazide (HCTZ) USPS. Magnesium 
Stearate6 was used as a lubricant. 
METHODS 
BULK/TAP DENSITY. 
Bulk density was determined by weighing the amount needed to 
fill a SO ml graduated cylinder. Tap d~nsity was measured by 
tapping the material until complete settling . All determinations 
were done in triplicate. 
~Sheffield Products, Norwich, NY 
3Foremost Whey Products, Baraboo, WI 
4DeMelkindustrie Veghel, Veghel, The Netherlands SDairy Crest .- Whey Div isi on, Suney, England 
6Sigma Chemical Company, St. Louis, MO Fisher Scientific Company , Fair Lawn, NJ 
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PARTICLE SIZE DISTRIBUTION. 
Particle size distribution was determined by shaking a 50 
gram sample of material on a Fisher Wheeler Sieve shaker for 20 
minutes . 
POWDER FLOW. 
Powder flow was measured using a Hettler PR 1200 scale 
connected to a Hettler GA12 chart recorder (1). 
PREPARATION OF TABLETS. 
Two hundred gram batches of the formulations were blended in 
a Wab Ambula mixing unit for ten minutes. The blend was further 
blended for three minutes after the addition of the lubricant. 
TABLET COMPACTION. 
Tablets were compressed using a Stoke's sixteen station 
rotary press. The press was instrumented with piezo transducers 
and interfaced to a Apple II personal computer. The details of 
methods used in tablet formulation and evaluation have already 
been published by Rhodes and his research associates (2,3,4, 5). 
TABLET EVALUATION. 
The weight of 20 tablets was determined using a standard 
analytical balance . The average tablet weight and its standard 
deviation were computed and expressed in mg. 
The thickness of 20 tablets was measured using a standard 
micrometer. The average t ablet thickness and its standard 
eviation were calculated. 
The hardness of 20 tablets was determined using a Erweka 
hardness tester. The standard deviation was calculated and 
represented as a vertical bar on the graphs. 
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The friability of 20 tablets was measured by comparing the 
initial weight with that after 4 minutes at 100 rpm . 
The disintegration time of 6 tablets was evaluated using the 
apparatus described in the USPINF XX -test #701. 
RESULTS AND DISCUSSION. 
PHYSICAL CHARACTERISTICS. 
From the results of the bulk and tap densities, the 
coefficient of compressibility was calculated as follows: 
7. compressibility = (DT-DB)/DT 
where DT 
DB 
tap density 
bulk density 
Table 1 shows the percent compressibility and the flow rate of the 
four products. The highest flow rate was observed for the 
Foremost product, which also showed the lowest 7. compressibility. 
A lower flow rate was obtained in the case of the Sheffield 
product . However, when actually making the tablets, no problem of 
flow was observed from the hopper to the press table, nor from the 
table into the die, for any of the products. Tablet weight 
uniformity was acceptable. 
The particle size distribution study showed that the 
Sheffield and the DMV products had similar properties with a 
respective percentage underweight of 517. and 417. through the sieve 
#150. The two other products appeared to be finer materials with 
797. for Foremost and 907. for Dairy Crest under the same 
conditions. 
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The results of the compaction study are shown in Figure 1, 
where the hardness of the tablets is plotted as a function of 
compaction force. For all products, as the compaction force 
increased, the hardness increased until capping occurred. 
DRUG CAPACITY. 
Figures 2 and 3 show the hardness of the 10% and 20% HCTZ 
tablets respectively, as a function of the compression force. The 
formulation of 10% HCTZ tablets showed acceptable levels for all 
products . At a 20% level of drug, the hardness of all tablets was 
lower. The differences observed from product to product in 
Figures 2 and 3 followed the trend shown in Figure 1. 
LUBRICATION. 
For each product, blends containing 0.2%, 0.3% and 0.4% of 
magnesium stearate were prepared and compressed at different 
compaction forces. Plots of the ejection force as a function of 
the compaction force has been previously used to evaluate the 
lubrication profile (8) . The lubrication profile of the Sheffield 
product is thus shown in Figure 4. As the compaction force 
increased, the ejection f orce increased, and the lower the 
percentage of lubricant, the higher the ejection force. An 
increase from 0.2% to 0 . 37. showed a significant decrease of the 
ejection force, whereas an increase from 0.3/. to 0.4/. did not show 
any further significant decrease. A c omparison of the four 
products was made at one single compression force of 5 KN. Table 
2 shows that the results were similar for all products . It 
appeared that 0.37. would be a reasonable level of lubricant. 
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EVALUATION OF TABLETS. 
The properties of the tablets made using the four different 
lactose products are shown in Table 3. Al l the tablets had a same 
weight of 350 mg and were compressed at a similar compaction 
force. Even though some variations were observed, it would have 
been possible to make tablets with acceptable specifications with 
all products. 
Rework was technically feasible for all four matrices, 
although the quality of the tablets obtained varied for the 
different excipients. 
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Table 1: Flow Properties 
Lactose 2roduct Lot II 7. comEressibilit:i flow rate 
gm./sec. 
Sheffield 4NL13 24 10.3 (0 . 6) 
4NL14 28 11.4 ( 1. 2) 
Foremost 1RA527 11 24.2 ( 1. 9) 
2RH431 10 29.0 ( 1. 9) 
Dairy Crest 635024 22 23.6 (0.5) 
635025 23 22.6 ( 1. 0) 
OMV A1369 25 23 . 8 (2.2) 
A0741 24 22.0 (1.1) 
a Average (Standard Deviation) from 3 runs . 
Table 2: Lubrication study (Compaction Force = 5 KN) 
Sheffield 
Foremost 
DHV 
Dairy Crest 
0 . 27. 
390 
380 
430 
350 
Ejection Force 
(N) 
Magnesium Stearate 
0.37. 
320 
330 
350 
250 
0.47. 
300 
310 
330 
240 
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Table 3: Evaluation of 10% HCTZ tablets. 
Lactose product Thickness Hardness 
inch 
_k_g __ 
Sheffield .173(.00l)a 10.S (O.S)b 
Foremost .177 ( .001) 3. 9 (0. 7) 
DMV . 176 (.OOl) 4.8 (1.3) 
Dairy Crest .177 (.001) 3.5 (0.8) 
aStandard Deviation from 10 tablets. 
bStandard Deviation from 20 tablets. 
Disintegration time Content uniformity 
min. % 
10 1.1 
17 2.4 
6 2 .0 
20 4.4 
-0 
-Table 4: Evaluation of 10% HCTZ tablets after rework. 
Lactose ;eroduct Thickness Hardness 
inch 
_k_g __ 
Sheffield .168 ( . 002)a 4.8 (l.3)b 
Foremost .165 (.002) 2.1 (0. 8) 
DMV .170 (.002) 2.8 (0.7) 
Dairy Crest .165 (.002) 2.0 (0.6) 
aStandard Deviation from 10 tablets 
bStandard Deviation from 20 tablets 
Friability 
% 
0.34 
0.25 
0.56 
0.55 
Disintegration time 
min. 
10 
20 
12 
20 
N 
-
-
FIGURE 1 
COMPACTION PROFILES 
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FIGURE 2 
DRUG CAPACITY (10% HCTZ) 
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FIGURE 3 
DRUG CAPACITY (20% HCTZ) 
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LUBRICATION STUDY 
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DESCRIPTION OF THE EXPERIMENTAL PROTOCOL 
1. Principle of the solubility method 
2. Preparation of the buffered solutions of cyclodextrins 
3. Preparation of the solubility v ials 
4. Description of the s olubility apparatus 
5. Time to reach equilibrium 
6. Direction to approach the desired temperature 
7. Sampling, filtration and dilution of samples 
8. Ultra-Violet analysis of the drugs 
9. Plot of solubility isotherm 
1. Principle of solubility method 
Higuchi and Connors described the solubility method in 
the 5th chapter of Advanced Analytical Chemistry and 
Instrumentation. An excess of solid drug is placed in v ials 
containing various known concentrations of the complexing 
agent. The solubility isotherm is then obtained by plotting 
the total drug concentration as a function of the total 
cyclodextrin concentration. Different types of 
phase-solubility diagrams may be observed. The type 
observed in this study was in all cases the A- type, in which 
there is linearity throughout the range of concentrations of 
the complexing agent. 
2. Preparation of the buffered solutions of cyclodextrins 
The solutions of cyclodextrins were prepared by 
dissolving known amounts of solid cyclodextrins in buffered 
solutions adjusted to the required pH. The buffered 
solutions were prepared by using monobasic and dibasic 
phosphate. The four characteristics of the buffer are: 
nature, pH, concentration and ionic strength. 
The buffers made were phosphate buffers. The buffer 
concentration used was 0.1 mole per liter. The ionic 
strength was adjusted to 0.3 mole per liter using potassium 
chloride (KCl). The first step was to make two stock 
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solutions, one of monobasic phosphate and one of dibasic 
phosphate. The concentration and the ionic strength of 
these two solutions were known . The second step was to mix 
the two stock solutions such that the pH desired would be 
exactly obtained . All the pH v alues were also checked at 
the end of the experiment at room temperature. 
3 . Preparation of the solubility vials 
Test tubes of ten or twenty milliliters were used to 
carry out the solubility experiments . The excess of drug 
was approximatively measured so that the solution would be 
saturated after equilibrium. The amount varied from drug to 
drug and from one cyclodextrin to another. The solutions 
were then added to the solid drug in the vial. The tubes 
were then tightly closed using screw- caps, and Parafilm 
strips were used to secure a perfect sealing of the vials. 
4. Description of the solubility apparatus 
The tubes prepared were placed and attached on the 
rotating unit . The rotating unit was immersed in a 
waterbath at a constant temperature in the range of 20°c to 
so0 c ( ± o.os0 c). A cooling unit was also used t o ensure a 
double source of energy thus allowing a better control of 
temperature. The capacity of the apparatus was about 70 
tubes, which corresponded to fourteen clamps each holding up 
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( to five tubes. The tubes were rotated until saturation was 
reached. 
5. Time to reach equilibrium 
Two solutions of cyclodextrins, namely 3 x 10-3 M and 
12 x 10-3 M were used to evaluate the time needed to reach 
equilibrium in the case of phenytoin at 20°c and pH 7. 
Samples were withdrawn and analyzed for drug concentration 
after intervals of time. The drug concentration was then 
plotted as a function of time, as shown in Figure 1. Even 
though the maximum concentration of drug was reached after 
about one hour, all the results shown in this study were 
obtained after a rotating time of two to three hours. 
6. Direction to approach the desired temperature 
In the study of the effect of temperature on the 
complexation of drugs with cyclodextrins, the same tube 
containing drug and cyclodextrin solution was brought to 
temperatures from 20°c to so0 c. There were two ways to 
change the temperature of the waterbath, one is to go from 
low to high temperatures and the other from high to low 
temperatures. In order to evaluate whether the direction to 
approach the desired temperature would affect the solubility 
results, a study was performed, in which the same samples 
were treated according to the two possibilities. As shown 
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in Table 1, there was no effect on the final drug 
concentration. In all the experiments, the temperature was 
then increased from 20°c to 50°c. 
7. Sampling, filtration and dilution of samples 
Samples of drug / cyclodextrin complex solutions of one 
to three milliliters were withdrawn from the tubes using a 
pipette. The samples were then filtered using glasswool, 
and filtration was shown not to interfere with the final 
concentration. An aliquot of 500 ul or one milliliter was 
then used to dilute the sample before analysis of the drug 
concentration. All manipulations of the samples were 
performed at the respective temperature by either working in 
a cool place (at 20°c) or in a walk-in oven (30°c to so0 c). 
8. Ultra-Violet analysis of the drug 
Tha diluted drug samples were analyzed using a diode 
array ultra-violet spectrophotometer. Standards of the 
respective drug were prepared by dissolving an exactly 
amount of pure drug placed in a hundred milliliters 
volumetric flask in twenty or thirty milliliters of 
acetonitrile. The volume was adjusted using distilled water. 
The standards had a concentration from ten to fifty ug / ml 
for phenytoin, diazepam and hydrochlorothiazide, and twenty 
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to hundred ug / ml for ibuprofen. The Beer's law was obeyed 
in all 
cases. The calibration curves are shown in Figures 2, 3, 4 
and 5 for phenytoin, ibuprofen, diazepam and 
hydrochlorothiazide, respectively. Cyclodextrins were shown 
not to interfere with the assay. 
9 . Plot of solubility isotherm 
In the case of phenytoin at pH 7 and 25°c, six tubes 
were prepared for each cyclodextrin concentration. The 
protocol was followed as described earlier. The final 
concentrations were plotted by considering the average value 
and its standard deviation as a function of cyclodextrin 
concentration. The results are presented in Figure 6. 
226 
227 
Table 1 
Direction of approach to equilibrium 
[co] x 10 3 M 
0 6 12 
T (oC) [Drug) mg/ml 
40 4.5 3.1 18.0 17.3 31. 8 31. 2 
25 2.7 1. 6 15.0 14.4 27.4 27.4 
10 2.0 1. 3 14.4 13. 7 26.6 26.5 
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Figure 1 
Time to reach equilibrium 
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Figure 2 
U.V. calibration curve for phenytoin 
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Figure 3 
U.V. calibration curve for ibuprofen 
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Figure 4 
U. V. calibration curve for diazepam 
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Figure 5 
U.V. calibration curve for hydrochlorothiazide 
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Figure 6 
Plot of solubility isotherm for phenytoin 
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APPENDIX D 
SUMMARY OF SOLUBILITY ISOTHERMS 
The following section contains the plots of the 
solubility isotherms obtained for the four drugs considered 
at different pH and temperature conditions. Some of these 
plots are already presented in Manuscript I and Manuscript 
IV. However, it was not possible to include all the data in 
the manuscripts, and this surrnnary may be useful to review 
the experimental results. 
The plots are presented drug by drug, as follows: 
1. Phenytoin 
Complexation with ~·en at pH 5 and pH 8 
2. Ibuprofen 
Complexation with ~ CD at pH 5 and 30°c 
Complexation with ~ CD at pH 2' 4' 5 and 6 
Complexation with ~ CD at 20, 30, 40 and 50°c 
3. Diazepam 
Complexation with ~ CD at pH 2, 3' 4' and 6 
Complexation with ~ CD at 20, 30, 40, and 50°C 
4. Hydrochlorothiazide 
Complexation with a, ~ and CD at pH 5 and 30°c 
Complexation with ~ CD at pH 5, 8 and 9 
Complexation with ~ CD at 20, 30, 40 and 50°c 
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COMPLEXATION OF HCTZ WITH ~CD AT 50°C 
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APPENDI X E 
STATISTICAL TREATMENT OF THE DATA 
The solubility isotherms obtained in this study 
correspond to the complexation of several drugs with 
cyclodextrins, at different pH values and different 
temperatures. The effect of these two variables on the 
slope of the plots of drug concentration vs. cyclodextrin 
concentration was tested for their statistical significance 
using a SAS program. 
The following section describes the datafiles, the Job 
Control Language (JCL), which was identical in all cases, 
and the results of SAS teatment of the data. The datafiles 
are listed for phenytoin, ibuprofen, diazepam and 
hydrochlorothiazide, respectively. The results listed are 
those obtained at a 95% confidence level (alpha= 5%), for 
the four drugs in the same order as above. The data were 
also tested at the 1% and 10% levels. 
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APPENDIX F 
NONLIN: PROGRAMS AND RESULTS 
As described in Manuscript II, the determination of the 
thermodynamic parameters using NONLIN, requires the use of 
three different programs: a datafile, a subroutine program 
and a Job Control Language (JCL} . 
The following section contains the listing of the 
programs used for the four drugs considered in this study . 
An example of datafile is shown for phenytoin, ibuprofen, 
diazepam and hydrochlorothiazide, respectively. Two 
different listings of subroutine programs are then 
presented. The first set of programs was used for the 
complexation of the non-ionized species of the drug with 
cyclodextrins. These programs are given in the order: 
phenytoin, ibuprofen, diazepam and hydrochlorothiazide. 
Following is the listing of the subroutine program, used in 
the case of phenytoin and diazepam, for the complexation of 
the ionized species with cyclodextrins . Finally, an example 
of JCL program and a listing of a complete output of the 
NONLIN program are shown. 
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ll =C11Ct11 
l:=l:XP< !:< I 
10 ~= < <ll*Hl+El*1206.~8 / 18.0 J *l0UOOOU,O 
H I HWEC 18 l .NE ,9) RE rLJRN 
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'-1.IA I ;; ,;;,. ·1 'UF: .I. , LJV 10 l. , l.IDM ' NU I L l NE N LIMl:<E~'l::.li, LI~ l Nb NUNLIM 
I:. 
~UBROUTINE DFUNC1~,p , coN,VAL•XoI•J•ISPECoXVEC•Y•W•NOl:<Sl 
1MPLIC1T REAL*l6 IA-H •K,0-LJ 
DlMEN SIO N ISPECll l,Nlll:<SllJ 
LIOUBL i:. P' l·\b.L lSJ.UN P' ( l ) •UAL.I l) ,p •X•LLIN( 1) ' Y\ 1 ) •W ( l ! .xvl::.L( 1 ) 
H=X•(l 8 .o•0.000001J 
J.l=l+NOBS( 1 J 
l =XVECi 111 
A=(~ i l)/(l,98 / *i l J-(Pl2l / l . 98 /J 
B=I Pl3>* <T-405.0ll/ll.987*405 .0• T>-Pl 4 J 
C=b.Xr' i iHL< I 
Li =•L/ i L+l) 
l:.=l:.H'( l:<J 
10 ~=((Li*H>+E > •(284. 7 4 1 18.0J•lOOOooo . o 
lF IISPE&<81 .NE,9 J RETURN 
ENV 
!:.ND DP Lili l A 
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lo 
S UBR OUilNE D l- UNCI FrP 1 C ONrVALr X r l•J·l ~~lL•YV~L•T • W •NL~S1 
lMPLlLll R~AL*16 IA - HrKrU -L) 
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H= x • 11~.o• u. 000001J 
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DATA SEl ' UR1.LJV101.10N4 ' NOT LINE NUMBERED• USlNG NUNUM 
E 
SUBROUTlNE UFUN C1 f-.P . CO N.V AL . x . 1 . J.1SPEC . x VEL•Y•W1NUBS) 
IMPLICll REAL*16 I A-H1K 10-L1 
UlMENSION ISPECCll ,NOB~lll 
DOUBLE PRECISION P l l l 1VAL ll) , F , X, CONlll 1Yll) ,W ll) , XVECl l l 
H=X*l18.0*0,000001l 
ll=l+NOB S< ll 
T=XVECClll 
A=< Y714 . Y5 /1 1.98/ * 1>l - 110.4// l.98 /l 
B=110040 .4* 1T-568 . 0ll/C1.98/*56~ . U * f>-5.505 
C=EX f-' I At Bl 
Ll=Ct<Ctl l 
l::.=l::.XPIBI 
b=CIV*H l t EI 
U= I P(l) /1 1 . Y8 1*1Jl-(P 12l/ l,98 7J 
V=(P(3) * 1T-568 , 0ll/11.98 l * 568 ,0*I 1-P\41 
UU=EXP I UI 
VV=EXPCVI 
Z= I UU*VVl-(UU*El 
(l=Z /I l+ Zl 
R=CVV-El* l lt <UU *VVll 
10 F=<<U *H ltGtk l * l252 .23 / 18.0 l *1 000000.0 
·IF < ISPEC('tt l .NE.91 RETURN 
END 
END OF DA TA 
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DATA SEl ' URl,LJVlOl ,NONLlN' NOi Ll NE NUMBEREU1 USlNG NUNUM 
~ 
//LJV10 1A J OB CLJV10111 ' MENA RD ' 1N01 1FY=LJV101 
/ *PASS WORD RLBG 
II EXEC NONL l NPHrREGION=~0 4 HK 
/ /D~UNC,SYSPRINT DD DUMM Y 
/ / DFUNC,SYSTERM DD DUMM Y 
1/D~UNC, SYSI N DU DSN=UR1,LJV101 , D M 1UN1DlSP=~HR 
/ /LK EU . SYSPRlNf DD DUM MY 
// UA I A.~f05~001 DD DSN=UR1.LJV101.DM14rUl~P=ULU 
// DA1 A,F T06F00 1 DD SYSO UT=A rHOLD =YES 
END OF DAlA 
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APPENDIX G 
SASGRAPH: PROGRAMS AND RESULTS 
The data of drug solubility as a function of 
cyclodextrin concentration and temperature were plotted 
using a SASGRAPH program. An example of the programs used 
is shown in this section for each of the drugs studied: 
phenytoin, ibuprofen, diazepam and hydrochlorothiazide. The 
results of the three-dimensional plots are then shown in the 
following order: 
1. Phenytoin: ~CD: pH 5, 7, 8 and 9 
2 . Ibuprofen: ~ CD: pH 2, 4, 5 and 6 
3. Diazepam: ~ CD: pH 2, 3, 4 and 6 
4. Hydrochlorothiazide: ~ CD: pH 5, 8 and 9 
303 
E 
10000 //LJVlOlA JOB I LJV1 01J , ' MENARD ' • llME=2 ,N OTlFY=LJV101 
20000 l *JOBPA RM L=20 
30000 // EXEC SAS 
40 000 //GO .F f llFOOl DD SYSOUT=A,HULD=YES 
50000 //GO,Fl l 2~001 DD S TSOUT=A•HOLD:YES 
60000 //GU.AOUT DD SYSOUT=A •DE ST=Q MSl 
70000 // GO.SYSIN DD * 
80000 DATA FlLEl; 
81000 I NPU T CD TEMP CO NCN; 
82000 CARD S; 
8300V 0 293 2 4,34 
8 4000 3 293 80. 4 2 4 
85000 6 293 1 42.96 
86000 9 293 204. 00 
8 700V 12 293 263,58 
88VOV 15 ~93 311 .82 
890VU 0 303 23 . 97 
8YlUO 3 303 84 . 36 
89200 0 303 142.8 4 
89300 9 303 208 .59 
89400 12 303 266 . 25 
89500 15 303 330 .0~ 
89600 0 313 34. 90 
89/00 3 313 99 . 35 
89800 6 313 160.87 
89900 9 313 228.2 4 
90000 1 2 313 296.53 
90100 15 313 351 . 8 } 
YV~VO 0 3 23 65 ,64 
90300 3 323 137 .39 
90400 6 323 189.02 
90500 9 323 259.75 
90600 12 323 328. 75 
90700 15 323 387.45 
90800 
304 
9 1U00 GU PIJ ONS NO TEX 182 DEVlCEmQ MS 1 200E NU~ULYGUN~l LL 
10000 0 CO LORS=CBLA CKI NOCIRCLEARC NOCHA RACIEKS 
110000 NODI SPLAY NOP RO MPT AUlUFEED NOFl LL 
120UOO NODA S H HA NDSHAKEmXON XDrP GSPLE N=132 
:UOOOO GE Nlt= ' BUSA. X GS!- NF1:-ll::.""(1U U I b;of MUVE= Af-·1·· UW r 
1 4 0000 TlTLEl J=L H=2 F =Sl MPLE~ L~BLALK 
15 0000 ' PH ENYlOlN/ CU PH:::, ·; 
1 600UO Tif LE2 JmC H=l . 5 F=Sl MPLEX c~BLACK 
1 700 00 
23 1000 t·' fW C SOR .. t ; BY i EMr' Cli ; 
23L00v ~ · kuL ~R!Nl~ 
2JJOOU PKUC GjGRlD Ocl ~Sl AI Si 
2J 4 UUO GRlV l ~M ~ * C D =CUNCN I 
2 J 500U AX1S2 = 0 10 1 5 BY 1 
2J6UUO AX1 S 1 =293 TO 323 BY 1 . 51 
2J/OOU ~RUC G3D DAT A=SlA I Si 
238000 PLDl TE M~ ~ C U=CONCN I SlD E GRlD 
239000 RO TATE =60 
23 '>'1 00 
239'-'00 
:2. ... "J'i..)Vij 
2~ 00<.>0 
2::ioouo 
f.Nli UI-
I ill 
ZMAX 
ZMlN 
-/-ti<- -
II 
llA .I A 
=6 0 
=800 
~o 
305 
E 
lOOU O // LJV1 01A JOB C LJ V 1 0 ll• ' M ~N A kU ' , f lM ~=~ •N U f!f- Y=LJVlV1 
20000 l •JOBPAPM L=2U 
.30000 II ~ XtL bAb 
4UVOU // uU. r I 1 lt-001 JI Li SYS UU r =A, HUU.1=n.,; 
~Ouvu // uU.~ 112rUU1 DD SYSUUl=A.HOLU= Y~~ 
60000 // uU.AUUI uu SYSUu f= A·D~Sr=GMSl 
/UO OO // GU.SYb!N DD * 
UVOOO DA TA F!L ~ l; 
UlUOU 1 N~U f LU f~ M ~ lUNLNi 
U200U CAkDSI 
8 3000 u ~YJ .3~.5 
U4 UUV .3 29.3 6 2 . 0 
U';JUOO 6 ~~.5 U6 .l 
86000 .,. 293 1 1 4 . l 
b 101,)(.) ].~ :~7' -5 14'i. :I 
t:H:.<000 l:::. ~·13 .l / .:!. • 4 
!j 'tUUU u .5U.5 4 ; ;~ 
8'>'1 0U 3 .50.5 // . ';:, 
t;'t2UO 6 .;o.5 io:.,, ~ 
!j't JU() y jOJ uu.4 
tj't 4 UU 1~ 303 16'/, / 
U'i~UU 15 303 ~()~~ . ;; 
U'>'6UU 0 .51.5 6q.6 
U'i/OU .5 .513 9 I ,'>' 
8Y800 6 3 13 1 2"1 . 2 
U9900 y .3 13 l 6t'» 4 
¥0000 12 JU 204 . / 
\l(J:l 00 1 5 .H.3 2.;u, 4 
Y02oo 0 .52.3 83..3 
9030 0 .5 32.3 120 .0 
¥0400 6 .323 157 .9 
Y0500 9 323 20.3.9 
'10600 i ··) ~ 323 242.1 
90700 15 323 285.0 
90800 
306 
91000 GOPTl ONS 
100000 
110000 
120000 
130000 
NUTEXr82 DEVICE•UMS1200~ NUPULYGUNFlLL 
COLORS•< BLA CK> NOClRCLE ARC-NOCHARALl~KS 
NODl SPLAY NOPROMPT AUTOFEED NOFlLL 
NOUASH HANUSHAKE•XONXO~F ~SFL~N•lJ ~ 
GEN D• '8U8A ' X GSF NAM E• AUUf GSFMUUE •A PPEND; 
140000 T ITLEl 
150000 
J•C H• 2 F=SlMPLEX C•BLACK 
'I BUPROFEN / CD PH 2'; 
160000 TifLE2 
1/0000 
J•C H•l, 5 F•Sl MPLE X L•BLACK 
~31000 PRUC SORT ; BY rE MP cu; 
232000 PRUC PR I NT; 
~33000 PROC G3GRID UUl •STAISi 
23 4 000 
23500 1 
2 .~6000 
23/000 
238000 
23'>'000 
239 100 
239200 
239 300 
2 40000 
250000 
UHi OF 
GklD TE MP*CD•CO NCN I 
AXIS2•0 10 5 BY 1 
AX1S1•293 ro 323 BY 1.5; 
PROC GJU UAIA•SIAlS i 
PLOT fEMP • CD•CUNLN I SlUE 
RO .TATE •60 
TI L·r •60 
ZMAX •1800 
ZMIN •O 
'* II 
DA TA 
. ; 
Gklll 
307 
91000 GOPTlONS NOTEXT8 2 DEVI CE=Q MS12001::. NOPULYGONflll 
100000 COLORS=I BLACK J NO ClRCLEARC NU CHA RALl l::.Rb 
110000 NODl SPL AY NUPRU MPr AUIUrl::.ED NOFILL 
120000 NUDAbH HAND SHAKE=XUN~Ur~ Gbrll::.N=lJ~ 
lJOuuo GENU ="8D8A ' X GSfNAME=AUUI GSr MUDl::.=APPl::.NDI 
140000 Tl TLl::. l J=L H=2 r=Sl MPLl::.X C=BLACK 
150000 'UlAZ E:YAM/ Cl1 r'H 6 ' ; 
160000 ll!LE~ J =L H=l . 5 r =S l~P ll::.X c~BLAC~ 
1/0000 ' I 
2,;1000 r'ROL SURI- I B) 11::.Mr' Cl.Ii 
2J~OOO PROC PRINI; 
233000 PROC G3GRID OUT= STATSI 
23 4000 GRI D TE MP* CU=LONCN I 
235000 AXIS2=0 TO 15 BY 1 
236000 AXIS1=293 ro 32J BY 1. 5 1 
~3/000 PROC GJD DAfA=STATSi 
238000 f-·LO I ! l::.Mr' * Cl1=t~ONLN / S l UI::. GR 1 U 
239000 ROTATE =60 
239100 llll =60 
239200 ZMAX =600 
239300 ZMIN =O 
2 400 00 I * 
250000 // 
END Ur LIA .TA 
308 
lOUUO l/ LJV10 1 A JOB (LJV 10l>• ' MENARD ' oTI ME=2oNUT1FYzLJV101 
20000 l *JOBPARM L=20 
30000 II EXEC SAS 
40UU0 /IGO , FlllFOOl DD SYSUUl=A,HOLD= YLo 
~0000 l/UU . ~11 ~ ~001 DU SYSOUl=~•HULD•Yl~ 
6UU00 l/ GO,AOU l DD SYS OUl =A oD EST•UMSl 
/OOOU /IGU.SYS lN DU * 
8U00U DAT A F l LE1; 
810UU INPUl CD lEM~ CONCNi 
b20()0 LARU bi 
83UUO U ~~3 4 1~ . ~ 
8 4 uuu ~ L~~ 0 6~ . ~ 4 
8~UOU 6 L93 856 . ~6 
U6UUU 9 293 1 10 4. 9 
U/ UUU 1~ ~93 130J,5 
bb v V0 l~ ~YJ 14 /8 . ~ 
b~U00 U ~03 9~~.0 
89 100 3 303 1091 . 0 
892UU 6 303 1326 ,4 
893UU 9 303 159~ , J 
UY4UU 1~ 30J 1669,0 
d9~0U 1~ 303 1Ul / ,o 
UY6UU 0 313 1361, 0 
U9 / UU 3 313 1568.~ 
U980U 6 313 1//4, 9 
89900 9 313 2026.5 
90000 12 313 2 128.5 
¥0 100 15 313 2518 . ~ 
iU~UU 0 323 22/1 , 3 
9 0 300 3 323 2 505 . 5 
90 400 6 3 2 3 2 6 7 1. 5 
9 050 0 9 3 2 3 2864. 0 
90600 1 2 323 3033 . 5 
9070 0 15 323 31 86 . 8 
9080 0 
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E 
10000 //LJV 101A JOB ILJV101) r ' MEN ARD ' rllME= 2 rNOT1FY=LJV101 
20000 l *JOBPARM L=20 
30000 II EXE C SAS 
40000 //GO .F 111F001 DD SYSUUT=ArHOLD =YES 
50000 //GO.Fl12F001 DD SYSOUl=ArHOLD=YE~ 
60000 //GO.AOUT DD SYSOUl=ArDESl=QMSl 
70000 //GO.SYSIN DD * 
80000 DATA FILEli 
81000 INPUr CD TEMP CONCN; 
82000 
83000 
84000 
85000 
86000 
8/0 00 
88000 
89000 
8'i 100 
89200 
89300 
89400 
89500 
89600 
89 700 
89800 
89900 
900 00 
YOlOO 
'>'0 200 
90300 
90 40 0 
90500 
90600 
90700 
90800 
\) 
1 
"> 
-~ 
4 
5 
0 
2 
3 
4 
5 
0 
2 
3 
4 
5 
0 
1 
2 
3 
4 
5 
293 
293 
293 
293 
293 
2 Y3 
303 
303 
303 
303 
303 
303 
313 
313 
313 
313 
313 
313 
323 
323 
323 
323 
323 
323 
CARDS; 
39.4 
186. 2 
316.4 
4 7 1.0 
5 82.8 
no.6 
3Y .8 / 
179.2 
327.0 
468. 0 
609.2 
'7 ::-.,2.9 
12.6 
218.2 
373 .6 
523 .0 
666.0 
837.8 
124.6 
258.8 
423.8 
562.4 
/06.2 
891.8 
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